Podcasts about adriatic

Ovidiu Nahoi discută cu redactorul șef al revistei Historia, Ion M. Ioniță despre destinul unei regiuni aflate la confluența imperiilor și civilizațiilor. Ce este Europa de Est?Ion M. Ioniță: Până unde se întinde Europa? Nici acum nu știm exact. Sunt doar concepte. Nu ar fi existat ideea de Europa de Est dacă i-ai fi spus asta unui polonez din epoca de glorie a Republicii Poloneze, a Commonwealth-ului polono-lituanian. Cred că s-ar fi uitat la tine și te-ar fi întrebat la ce universitate ai terminat – că la Universitatea Jagiellonă, sigur nu ai terminat, pentru că acolo era centrul.A fost o perioadă, după '90, tulbure în România. Știți, când tot felul de povești circulau despre românii care nu știu ce fac prin Viena și așa mai departe. Și a existat această imagine și în Polonia, legată de diverși emigranți plecați din România.Dar lucrurile s-au schimbat foarte mult. Suntem parteneri, avem legături comerciale, legături economice puternice, dezvoltare de firme, avem firme românești în Polonia și — poate o să zâmbiți — dar nu facem reclamă, vorbim despre realități: una dintre firmele pe care le vei vedea pe bulevardele poloneze, așa cum le vezi și în România, este Luca. Cei cu covrigii.Sperăm să apară și alte exemple de succes, dar ceea ce vedem acum arată că suntem din ce în ce mai aproape. În plus, au apărut noi linii aeriene care leagă direct România de Polonia, și asta este extraordinar.Polonezii mi-au spus că interesul lor pentru România a crescut mult. A fost o perioadă în care, trebuie să recunoaștem, imaginea noastră în Polonia nu era tocmai bună. Dar în ultimii ani, lucrurile s-au schimbat. Nu mai vin cu Fiat Polski, cum veneau în anii '70–'80, cu mașinuțele acelea mici, încărcate cu tot felul de lucruri pe care le schimbau aici. Era o vorbă, pe vremea comunismului, când totul era la negru: «Dacă nu faci negoț, nu trăiești». Ca să trăiești, trebuia să dai ceva la schimb. Iată că vremurile acelea au trecut.România începe să capete interes și din punctul acesta de vedere – al ofertei turistice pe care o are. Încă o dată, avem o mentalitate comună. Vorbeam de câteva puncte de interes în Europa de Est, pentru că am avut și o istorie comună.Mă refer în special la împărțirea din '40, la prăbușirea comunismului și la ceea ce a urmat. Evident că n-am reușit să construim Uniunea Europeană sau NATO cu participarea întregii Europe, pentru că, din păcate, la sfârșitul celui de-Al Doilea Război Mondial, o parte a Europei a căzut în lagărul comunist. La acea vreme, nici nu exista conceptul de 'Europa de Est'. A apărut mai târziu. Nu el [Churchill] a trasat-o propriu-zis, dar a fost cel care a pus în conștiința lumii ideea că există o Europă de Est, separată de restul continentului. În celebrul discurs rostit la Fulton, Missouri, vorbea despre cum ‘o cortină de fier a coborât peste continent', lăsând în umbră frumoasele orașe ale Europei – de la Baltică la Adriatică – și le enumera pe toate, inclusiv Bucureștiul. Atunci s-a născut conceptul Europei de Est.

Lee Haskell, chief commercial officer for Celestyal Cruises, talks with James Shillinglaw of Insider Travel Report about his company's recently completed season cruising the Gulf of Arabia. He also previews the season where Celestyal will sail two ships in the Aegean and Adriatic. For more Information, visit www.celestyal.com.  All our Insider Travel Report video interviews are archived and available on our Youtube channel  (youtube.com/insidertravelreport), and as podcasts with the same title on: Spotify, Pandora, Stitcher, PlayerFM, Listen Notes, Podchaser, TuneIn + Alexa, Podbean,  iHeartRadio,  Google, Amazon Music/Audible, Deezer, Podcast Addict, and iTunes Apple Podcasts, which supports Overcast, Pocket Cast, Castro and Castbox.  

Wrapping up loose ends and moving forward.Book 3 in 18 parts, By FinalStand. Listen to the ► Podcast at Explicit Novels.Love is like a crossbow quiver. You only have so many bolts to shoot before it runs outThere was a long pause. Pamela took another long breath then an impish grin came to her lips."With your luck you'll get those, then end up in the Artic," she scoffed."Not the Antarctic? I've got a soft spot in my dreams for penguins.""Nope. You get to be chased by polar bears," she nudged me. I nudged her back playfully. She gave me a Charlie horse."Ow!" I yipped. The two SD chicks from the front of the plane looked back our way. I didn't care about their misconceptions. My muscles needed some self-massages."I was pretty scared," I whispered to Pamela."Good for you. You were also pretty lucky and I'm sure pretty pissed with your 'Albanian' attackers," she replied quietly. "I missed you too."I liked the way she read my mind about that. I would have liked it some more if I hadn't glanced to my other side, then fallen straight to sleep.{1 pm, Monday, August 25th ~ 14 Days to go}On Tuesday night, Aya got one of her wishes fulfilled ~ sorta. I slept in Caitlyn Ruger's bed and I wasn't alone. The Sandman had dropped a Scottish sand trap sized load of sand on me and there was more than enough spillover to flatten little Aya too. Because I lived among Amazons, Caitlyn woke me up at 5:45 in the A M and only so much lollygagging was allowed.Aya got to sleep for fifteen whole minutes more than I did. She hugged me and kissed my cheek (which amused her three Fatal Squirt compatriots to no end) while I stuffed away my breakfast. Desiree showed up to take me to work minutes later. While Aya showed off her battle scar to the pre-caste Amazons and her Aunt D. (they had not been awake when we showed up the previous evening), I was chided for being late for weapons practice.Yes. Life and death battle successes meant nothing to the Amazons. If you had a spare moment you had better be training, or working out your mind and/or body. We had no 'weekends', though we did get an quarter day off in celebration for the religious festivals based on the sacred days of the various matron Goddesses. A full day off didn't happen.7:00 AM saw me with the intern group, just as if nothing had happened to change our relationship over the past two months. Oh, we were different. They teased me about my sunburn and wanted to see my latest scars. I couldn't work with Buffy anymore, since I was her spiritual leader. Due to my 'high risk' status, Desiree was the only other Amazon Katrina trusted me with, so I got to get beaten at her hands for the last three days of the week.To be fair, I teased Desiree incessantly. I made her smile when she thought I was doubled over in pain on multiple occasions. Beyond that seven-to-five schedule, I exercised after work until six and then managed to bike home in a manner that avoided the paparazzi.I was easy to track outside of the building by the members of the press (who thought I was still somehow newsworthy) and despite my persistent desire to not talk to any of them. Felix had 'vanished', so I was the only man left. What had happened to him? Katrina allowed me to take a glance. He was at an Epona Wyoming freehold training for the Great Hunt and reveling in his 'lone man in a household of twenty-two single women' status.Unlike the three other members of our 'first class', Felix got to choose his re-location location and communicated with me daily because he wanted us to create a battle plan for the upcoming Hunt. It was official; it was going to be a two man vs. thirty Amazons affair and there was no rule that we couldn't work together though only two Amazons could win by capturing us and holding onto us until sunset on Sunday, September 14th.No one except Krasimira, the Keeper of Records, knew what terrain we would be hunted on so we could expect anything from swamps to mountain ranges. The Amazons were in the same boat. Already the House heads had volunteered one member for the Hunt. The ancestors would be consulted for the half who would actually participate. Krasimira had also added her own twists.House Ishara couldn't compete because technically, I was already their participant. With 52 houses halved, that equaled 26. The final four? Runners. If a runner won, the Keeper would consult the ancestors to see which house they would automatically be inducted into. Eight runners were nominated by the department heads and four of those would be chosen by the Augurs as well.In a normal organization it would have been thought that Krasimira was abusing her station since there was no High Priestess to oppose her decisions. Not in the Amazons. No. She consulted the Augurs and the Augurs worked the will of the Ancestors and that was that. No Augur would lie about the sacred communications imparted to them. That was inconceivable sacrilege.What that did mean was that at sunset on Thursday, September 11th, Felix and I would be inserted with a knife, map and clothing into the hunting zone. When the sun rose on Friday morning, the thirty Amazons would be put into the zone. No Amazon could attack another unless they, or their targets, 'possessed' a man. They could team up but only two could win. It was promising to be a great 'get to know your buddies at work' moment for all of us,What was Felix getting out of this besides his freedom? (His freedom was no longer in danger. House Epona would protect him.) No, for Felix, if he survived free until the sun set on Sunday, he would become a Runner. If he lost, he would have to spend another year as an intern. This convinced me that Felix was totally dedicated to avoiding capture. I was good with that.Meanwhile for me, it was Brooke Wednesday night, Oneida on Thursday and Timothy and Odette going clubbing with me on Friday night. Saturday was my first House Ishara group activity. We gathered in the early morning at Doebridge, me with a hangover and Buffy giving me crap at every opportunity. Fortunately the rest of my 'sisters' treated me with a great deal more reverence.Now they all knew about my Summer Camp role, Romania and my kidnapping. Even in their 'man-hating' ideology, I was the exception to the rule ~ I was reliable, dedicated, smart, lethal and worthy of their trust and respect. On the council front, Buffy hinted to me that there was a way around the deadlock for who would be foisted onto the Regency Triumvirate, but she refused to tell me what it was. That was a cause for concern.Sunday, I worked with JIKIT, did some Amazon diplomatic stuff and discovered Desiree was my new bodyguard. Katrina thought a full SD team would be cumbersome and my best bet was to remain unconventional and mobile. I agreed because it allowed me to play the field a little more. Speaking of playing the field,This bright Monday afternoon, I was standing in a hangar at Stewart International Airport waiting on my fiancée, Hana Sulkanen. She had flown from Tibet to London with the Dali Lama. That exalted individual had passed on the mantle of national leadership to the Tibetan Constitutional Committee and left the country with the stern decision that the country would move forward toward democracy and not backwards toward theocracy.Now he was playing the role of goodwill ambassador, encouraging the Tibetan Diaspora to spend a few months to a year back in their homeland to help rebuild and teach. He also was rallying support for Tibetan recognition and financial support. Already the UN had voted to send a small international group to establish border security against both the Khanate and the PRC.With the PRC treaty-obliged by the ceasefire to not oppose Tibetan freedom, the UN acted rapidly. The UN Tibet Force(UNTFOR) combat elements consisted of the UK (+ Gurkha), Chilean, French (+ French Foreign Legion), Germany, India, Italy, Romania, Spanish and Thailand each sending one battalion each. Algeria, Denmark, Chile, the Netherlands, Bulgaria, Canada, Cameroon, Qatar, Saudi Arabia and Brazil agreed to make smaller contributions. The USAF would supply a serious level of logistics support for the mission.The UN also created the UN Tibetan Training Force (UNTTFOR) which provided a structure for giving access by Tibetan forces to German, Italian, Chilean and Romanian bases to train to E U standards over a five month period. The Khanate provided gobs of captured Chinese hardware to the creation of a tiny Tibetan Armed Forces, easing worries about adequately equipping the troops once they were trained.The Dali Lama was simultaneously arriving at JFK to public fanfare in order to thank the UN personally on behalf of the nation he loved. Hana was able to finally shed the limelight and was coming into a secure National Guard facility to finally take a step back to a 'normal' lifestyle. The last bit of oddity: the hangars used by the Marine Aerial Refueler Transport Squadron 452 of the Marine Corps Reserve was courtesy of JIKIT. No press was allowed, or expected.It was an odd grouping of us. Jormo Sulkanen (Hana's father), his chauffeur and Hana's daughter  Annela were in one car. Hana was traveling with Libra and Ms. Meacham, so they would need the limo he came in. My appearance was a simple moment for us to touch base in person, as opposed to over the internet, or mobile phone. The third group waiting was Sten Phillip M nnik (her ex-husband) and two unnamed associates.Sten was being a total jerk, which may have been due to me calling him Philip when we first met. Philip wasn't 'ethnic' enough for him, so he never used it. Because he hated it, Brennan (Hana's deceased step-brother) had used it constantly. I had overheard it and thus screwed up our first meeting. But Sten's current blistering hatred had two positive side effects: Jormo came over and stood by me, a suggestion of solidarity I hadn't expected, and since we were standing next to each other, we finally began the dialog that we needed if Hana was going to be family to both of us.We chatted about the thing that mattered most ~ Hana. He asked me if I had really hired a team of assassins to protect her, so I told him a little bit about the Ghost Tigers. He talked about how proud she was to be bringing peace to a suffering planet and I agreed that she looked spectacular doing so.Some things remained the same; I had set in motion the death of his youngest son who had paraded a raped lady in front of me. A bunch of other dilettantes had perished as well. Balancing that was the joy I brought to the child closest to his heart, his adopted daughter Hana. I also had proved to be my own brand of eccentric knight in tarnished armor. I meant well, and in Jormo's book that meant something.He also told me he would strangle me with my own intestines if I broke her heart. I looked him straight in the face and asked him how he felt about open marriages. He hit me. To be fair, I let him hit me. He didn't try to do me serious harm."Don't be an asshole," he grumbled."I'm not sure I know how?" I shrugged. I got another hard stare."She loves you," he said with surprising tenderness."I would rather face that typhoon again than break her heart. The thought of that scares me because I've never been all that good at romance," I confessed."That wasn't what I expected you to say," he harrumphed. "I recall those two ladies I first saw you with. Libra Chalmers and,""Brooke Lee," I said."Yes, her. Are you staying loyal?""She has never asked more than she thinks my current level of maturity can hope to achieve." He looked at me. "I'm discrete and mindful of her sensitivities.""You aren't trying to befriend me," he noted."I don't feel it is right to expect you to like me. I think we both know I'm supposed to be nice to you and you aren't going punch me again. I believe Hana would see thru any deception on our part."I paused. "I wouldn't mind us getting along. I'll try not to piss you off because that would be rude to you and cruel to her," I continued. "I'll never ask you to forgive me and I'll never feel like what I did was inherently unjustified. I am sorry that I caused you pain because I think you are a hard, courageous man, and she loves you.""That's her plane," he stated."Thank God," I muttered. And thank you Ishara. I was starting to blather. We remained thankfully silent until the plane had pulled into the hangar and the people started to deplane. The first out was a young woman with dark blonde hair and hunters glasses.No one else appeared until she had reached the bottom of the stairs and continued to look about for a moment. Hana came next, smiling at me, then her eyes were following Jormo as he moved to the car to retrieve little  Annela. Libra followed with Ms. Meacham on her heels. Libra still wasn't used to playing the second fiddle/personal assistant. A short Mongolian fireplug of a man was the last passenger down the stairs. He looked like, a wolverine with his feral, primordial energy and general hostility.I imagined the girl was his apprentice and he was the prime assassin. That was how the Ghost Tigers operated. They were doing me a deep personal favor by putting aside their normal role as hunters to take up body-guarding duties. According to Addison, they had also managed to get their fair share of killing people of various persuasions. Not only had the Seven Pillars tried to take her out more than once, Chinese Intelligence and some criminal cartels had taken an active interest in her too.The young woman scanned from me to Desiree, then to Sten. She had a good eye for threat assessment. Jormo was partially concealed, but would rather die than put Hana at risk. I was the ally of the 9 Clans, and she probably thought she could take me in a quick-draw contest. Desiree? She left Desiree for her mentor to worry about."Ms. Sulkanen?" Sten's closer minion walked her way. The bodyguards got in the way instinctively. The man reached into his coat and nearly died. The women did a palm strike to his windpipe then grabbed his tie, yanking him to the hard concrete floor of the hangar.(Russian) "He has a piece of paper," she stated in a detached manner"Sten, what is the meaning of this?" Hana worried. I moved toward the woman.(Russian) "I am Cáel Nyilas. Let me help."She did more than that. She retreated from the downed man and put her body between Hana and Sten.I was schooled enough now to realize that was the deception. I hadn't seen the older man draw a gun but I knew he now had one out. It was down by his side and he was using his body to shield it from view."Are these the kind of people you want around our daughter," Sten asked haughtily. I had an inkling suspicion. I wasn't alone.Desiree pushed past me and attended to the downed man. She had him standing, patted him on the back and frisked all inside ten seconds."He's a process server," she commented to the group."What he is here to do is serve you with papers, Hana," Sten grew angrier. "You are an unfit mother and have developed an unsafe environment for her to grow up in.""What?" Hana growled. "You don't like the fact that I've finally moved on and found someone new. You don't care a damn thing about our daughter.""We will let a judge decide that. Right now I have an order of detention for  Annela," he grinned wickedly."Ms. Sulkanen," the second of Sten's minions step forward more cautiously, "the Family Court in the State of New York has,"I laughed."Oh," Desiree looked my way then shared a sliver of a smile with me."There is nothing laughable, I assure you," the lawyer snapped."Really, what's your name?" I asked."Mr. Dornier, not that,""Where are we?""What does that matter?" then, "New York State.""Incorrect Dornier. You are on a Marine Corps base, dumbass. Look around you," I smirked."So? What does that mean?" Sten harangued us."This is federal property," I explained as I strode toward his car."Hey, what are you doing, I'm talking to you," Sten pursued me."Excuse me," I grinned. I flipped out my Amazon Honor Blade and slashed one of his tires."What?""Go for it," Hana simmered. "Touch Cáel and he will defend himself.""He has a knife," he countered. He didn't touch me. A second tire began to deflate. "That's assault with a deadly weapon.""It would be if he turned to face you, or anyone else," Desiree had her 'bored ~ don't press me' voice. "Right now he's being a vandal." She put her hand on the process server's shoulder and shoved him back toward Sten and Dornier. "You should know your jurisdictions, asshole," she told him."Hana, I will drive back with Cáel," Libra announced loudly. That was a cue for Hana to shoot me an apologetic look, which was odd, considering that even knowing me was putting her child custody at risk. It took me a second to realize what a bastard Sten could be. I also doubted he had three spare tires. I left one untouched as I headed for my car."Hana, I'll catch up with you after you talk with your lawyers," I called out. It was infuriating for me that this was her reception home. Sten had better be thanking his lucky stars we weren't alone or I would have pummeled his ass, and given him the nuclear wedgy of all times, jackalope."Let's go home," Libra tapped my arm. Desiree was watching Jormo's limo speed away. She didn't dawdle. The Marines would want their hangar back ASAP. We'd let them decide if they wanted to help Sten, or not. Desiree tossed me the keys. That was her way of telling me I need to blow of some steam, and not by getting frolic-ee with Libra on the hour long commute home.{11 pm, Monday, August 25th ~ 14 Days to go}{Late that night with Hana}"So, who was the guy who gave you this?" I looked over at Hana while running my hand over the silk scarf some lama in Lhasa had given her to give to me ~ a 'Thank You' gift for the liberation of his homeland and the aid package heading his peoples' way."I never got his name, but my translator said he had traveled for three days straight to be there for the celebration," she smiled warmly.I picked up my second gift and began to play with it. The object was a fascinating toy, all the more so because it was more than a child's plaything. It was a simple prayer wheel. I put the handle between my two palms and rubbed them back and forth, causing the two balls to beat against the drum heads."I think you find that thing more interesting than you do me," Hana pouted."Oh no you don't," I pounced on her. With one hand I tickled her while I placed my Tibetan gift aside. I didn't want us rolling over on it as we frolicked naked on her queen-sized bed. "You were a happy little camper ten minutes ago and you certainly drove your vigor home with this grand Lothario.""Eek!" she playfully tried to bat my hand aside. She began giggling hysterically.Even when I pulled away so that she could breathe, she kept snickering."What?" I worried. I had been ramping us up for a second round of sex. Round one had been 'comfort' sex, helping her compartmentalize her feelings for that bastard of an ex-husband and the threat he posed to her custodianship of her daughter,  Annela.Those were emotions she'd deal with later. Fretting about them tonight, her first night back in the States, was counter-productive. She knew that, which was why she'd accepted my dinner invitation. We had now been seen in public together for the first time since she became famous; afterwards we had traveled back to her place. How serious was I about cheering her up? I'd brought a spare suit, biking clothes and my bike. I was planning to spend the night and make my way to work my usual way come sunrise."I," she gasped, "asked Libra how you "compared" in her experience, which seems to be extensive, as a lover on the way over. And after several, very long, I must say, seconds of introspection, she told me you were indescribable and incomparable. I've been trying to put my thoughts together since Rome and, why are you scowling?""That was rude of you two," I now play-pouted. "I like to think I'm 'thunderous', though 'stunning' will do in a pinch."Hana helpfully pinched me. "Ow!" I squalled. And back to tickling I went. I quickly showed her my 'sheet-fu' was superior to hers, which meant I tangled her up in her sheets before she realized she was helpless before me. Or so I bragged. Hana played helpless well."Oh please, Mr. World-Conquering Wombat," she pleaded. Wombat?"Wombat?" I questioned her. "How have I become an irascible furry marsupial?""Well Honey, you need a shave," she teased me. "You are a little furry.""Romantically that is called a five o'clock shadow," I protested."It scratches my thighs," she murmured.I had a remedy for that. Sliding down to her hip, I turned my palms toward me, interlaced my fingers and positioned my thumbs pointing up. My chin rested on my fingers and the thumbs covered the sides, so when I stuck my tongue into the three-sided void created, my hands, but none of my scruffiness, touched her intimate flesh. Once I had this technique in place, I rolled over her thigh and got to work."I find," she gasped, "that you have the answer to that conundrum down pat. It makes me, ah, think I'm not your, ah, first girl." My dedication to my erotic task (and the carnal reward that waited) kept me from responding. Besides, my upper lip was busy rolling back and forth over her clitoris. There I let the bristles of my oncoming moustache teasingly tickle her. I was pleased when the pleasure I caused quieted her and she settled down to running her fingers across my crown as she ramped herself up toward a climax. 'Not my first girl' indeed.Forty-five minutes later, I was coming back to her room from the kitchen with a glass of tomato juice for her and rice wine for me (she was out of beer). I heard a noise from  Annela's room, so I deviated to make sure she was okay. I was in boxers, not totally naked.  Annela was out like a light, caught up in some sort of childish dream. By the cherubic grin on her face, she was having a good one.She was another delicate female issue in my life. I had made her existence harder by just being me. Hana let me know that nothing 'bad' had better happen to her ex-husband, Sten. I couldn't beat him up, threaten him, or sic any of my Amazons on him. Stupidly, I had asked if using the CIA was okay. She'd banned all of JIKIT intervening as well, negating the use of the best pest removal people on the planet, the 9 Clans."You are going to have to get used to children making sounds while they sleep," Hana surprised me. "You'll learn to tell the dreams from the nightmare.""In spades, I'm going to have to learn that in spades," I nodded.{4 pm, Tuesday, August 26th ~ 13 Days to go}My schedule had remained steady. I had firearms practice at 6 am every morning, was in Katrina's office by 7 and working my cue by 7:15. According to my regular morning briefings, I continued to be a menace to the foundations of freedom, civilization and the terrestrial biosphere. It was wonderful to stand there side by side with my fellow New Hires.At lunch, around 11 o'clock, I had a brief get together with the other members of the Amazon diplomatic corps since I was still Chief Diplomat of the Host ~ we were a small unit. Daphne, who now worked with JIKIT, would give me a brief briefing on what the 'office' was up to in my name. I gladly kept my distance from their regularly scheduled mayhem. The truce in China didn't stop the Secret War from raging on and on.My three o'clock knife training with Pamela was slowly evolving into a greater study of human fighting philosophy and anatomy. I still studied the techniques of a larger single bladed hunting knife as well as the hilt-less, double bladed Amazon Honor Blade. Pamela promised me she'd start teaching me how to do the 'long-distance' and 'short'/snap throw for the blades. She made it look so easy.Pamela also began educating me on the basics and basis of the Amazon personal hand-to-hand fighting style. The eight points of emphasis in Amazon combat were: the finger, fist, elbow, shoulder, foot, heel, knee and hip. It encouraged channeling both your energies and the energy of your opponents by using fluid blows and throws. It also worked well with the close-in knife fighting Pamela was teaching me. Working with her once more did her as much good as me. We had come to feed off one another's moods, which was a good thing.Tuesday, walking to the elevator at the end of the session, the door opened to reveal Rachel talking to an SD chick I barely knew, Meridian."Oh, it is great to see you, Rachel," I enthusiastically stated. Her hesitation as she replied worried me."It is great to see you too, Cael Wakko Ishara," she responded softly, compassionately."Ladies, can you spare Rachel and I some private time," I asked Meridian and Pamela."Come on," Pamela addressed the SD Amazon, "we have tons of nothing to talk about.""As you wish, Ishara," Meridian answered. She looked to Rachel. She stepped off the elevator as Pamela stepped on. Away they went."I heard you were back in New York," I told her."I heard you were off of JIKIT for the time being.""I was running on fumes psychologically and my body wasn't too much better. Javiera gave me a week off. I go back Thursday.""That was the right move, Cáel," she said. "You've been stuck sweating both the small stuff and being caught up in the big picture. That is a humongous burden to bear for someone with your training and background.""I know, I'm not ready for where my life has taken me.""No one is, Cáel. You have training that has let you get this far when most of us would be lost. You carry that weight, plus you've had to work the physical side of the equation. I get to focus on you. You've had to focus on all of us."Rachel was being both honest and kind. I felt a sudden renewed kinship with my primary guardian."Thanks for that, Rachel, can I tell you a secret? Something you can't tell another soul. Something I've never told another living person?" I could tell Rachel. I couldn't tell Katrina because she was so close to Hayden. Pamela, Pamela had already prepared herself for a miserable afterlife and wouldn't have connected with my pain for another.Since she was my 'sister' in Ishara, I couldn't really confide in Buffy, but only an Amazon would understand my thoughts on the matter. It had to be Rachel."I cannot betray the Host, but you know that. What is it you wish to share?""Hayden lived life as an Anahit, yet lives forever in the Halls of the Isharans." Since that was now well known, Rachel knew that couldn't be the secret."When I was trying to induct her, Dot Ishara refused her entry. I thought she was challenging me and I was right.""I recall that she wouldn't accept Hayden, even though her death was righteous in the name of the Host. Has no one ever asked you what changed Ishara's mind? Not Buffy, or Helena?""Neither one ever asked. I think it was because they sensed I didn't want to talk about it, nor insult them by not opening up. Ishara refused Hayden because of me. I was refusing to accept my place in the Host. I kept playing, pretending, I was not really one of you. I kept thinking I could divorce myself from the evil we did because I was special.""But you weren't special in the way I think you are using the word," she nodded. "You were chosen by the Ancestors to be one of us, man, or not.""Yeah. I stupidly put my life on the line because I wanted to be the 'good guy'. I've always wanted to be the 'good guy', even when I hurt people. I'd tell the girl it was my fault, yet I excused that behavior by thinking that I hadn't meant to hurt anyone, so I was okay. I have never blamed myself for any of the shit I caused.""That has always been a rather annoying quality of yours," she noted."When I was on the roof of Havenstone, daring Ishara with my life on the line, that's when I felt it. I owed and owned my Amazon heritage in that moment. I finally blamed myself for something, for not accepting sacrifices were being made for me and I was dishonoring every one of you by denying their purpose.""You are Ishara," Rachel stated firmly. That was her entire argument."I had to believe that. I had to believe I was nothing more than one Amazon in a long line of Amazons dating back to that first night of betrayal. I had to realize I was one of many, not someone special, with special rules. I wasn't getting to be the good guy, or even the bad guy. I was just, an Amazon. One more Ishara among the hundreds that stood in my place.""And it took that moment for you to realize what most Amazons know from the age of five," Rachel stroked my cheek. "It is easy for us to forget your bravery comes from a place that is uniquely you and you didn't grow up around the fires with tales of our mothers, grandmothers and all those who have come before. We see our honor is gold and sing the songs in the First Tongue. We live as Amazons.""I wanted you to know because," I faltered at the last memory."Charlotte. You want to make peace with me about Charlotte," she touched my cheek yet again. "Cáel, I told her mother and daughter about how she died. They want to meet Vincent when he is feeling better. They want to talk to you. They worry about you not understanding that Charlotte lives and will live on until the Sun dies and the stars burn out.""Charlotte was in the Warband that killed Ajax the Unconquered, Cáel. She fell on that ridge, looking down on Ishara's triumph over Ajax and her spirit took the news of that victory to the next life. She is a welcome exemplar to House Ska i. She will be remembered in the lists of the Security Detail, our Warrior Elite. Charlotte was my friend and I didn't wish her to die, but war is what we do. And she buried her enemies and saved our lives."Ska i was a j tunn and the Nordic goddess associated with bow-hunting, skiing, winter, and mountains. I had known her house. The SD didn't talk about their families much because of their devotion to the craft of war, so I had never known her mother was still alive, or that she had a daughter."She did much more than die, Cáel. She killed men so that when you finished with Ajax, none of them, left on that field, could avenge him," she added."I hadn't looked at it that way," I confessed. "I'd like to meet her family. You said she has a daughter. I didn't know.""You didn't need the distraction. We all knew you would have only done incredibly stupid things trying to keep us alive. If it helps, she is five and cried freely, deeply and long. Her mother is fifty-two and runs a freehold in Saskatchewan. She'll be around for a long time, trust me."Charlotte's mother had to be one tough D O B (daughter of a bitch) to see sixty. I did know she was the second of five daughters, with the middle one being in the Ska i House Guard."I am doing something for, well, for me, but for Charlotte too. Sakuniyas is leading seventeen House Isharans and two ladies from MI-6 in West Africa.""I'd heard about that," she smiled. "Charlotte's Fist." Four (the core of any war band) was a sacred number to the Amazons, as was five (the number of digits) so twenty was a classic warrior unit. It was also the number of the original houses. Normally these groups were referred to by their leader's name, but I wanted the Condotteiri to know they'd killed the wrong Amazon and Sakuniyas agreed to the naming convention.The Condos had sent Ajax to Hungary and Romania to kill me. Charlotte had died stopping them, but this was not a matter of revenge. This honored her and was a request for her to watch over those who sought inspiration from her when they went into battle. West-Central Africa was one of the three Amazon Homeland (Eastern Europe and Southern India being the other two) and was where the war was heating up.JIKIT (Joint International Khanate Interim Taskforce) became involved when the Condos and Coils of the Serpent (one of the 9 Assassin Clans) began killing local civilian and military leaders. The Condos did it to spread chaos for them to use as a smoke screen behind which they could hide the large numbers of mercenaries in the area hunting down the Amazons. The Coils attacked any official that was on the Condo's payroll.As the body count began to rise, the US and UK began having 'normal' covert agencies investigate the killings, yet they remained blind to the reasons behind the actions. It wasn't until a whole Condo 'training camp' ended up being extinguished that they realized there was a third player in the game (as opposed to the governments and the rogue mercenaries).The Coils of the Serpent were one step ahead of the intelligence agencies. And that allowed the Amazons to hunt down the Condos. We in JIKIT had estimated it was roughly 15,000 Condotteiri foot soldiers (consisting of mercs, local paramilitaries and the occasional regular army commander) versus the roughly 3000 Amazons and 1000 members of the 9 Clans. The Golden Mare was asking for Havenstone and the Freeholds in North and South America to raise up 'fists' to join the struggle in Africa. In Belize they would be trained for two months to ten weeks in jungle warfare before heading over."Are your people going to be ready?" Rachel inquired."We have done well in Japan," I replied. "The former 'Runners' actually do better moving through urbanized society than their Old School Amazon sisters.""I heard they are more prone to taking orders from the Ninja," she looked me in the eyes."I told them to. This is the Ninja's war and we serve them best by doing what we do best ~ taking the fight to the Seven Pillars when they expose themselves," I clarified. "And you got me off talking about Charlotte," I realized a second later."A long period of mourning is not our way, Cáel," she confided. "You were our friend, but you were our mission first and foremost. That hasn't changed.""Are you going to," I began to say 'remain my bodyguard'."Yes. I have a dozen House Guard members expressing a desire to join the Security Detail and be our new electronics expert. Eight of those I'm giving serious consideration to.""The other four?" I asked."Three are too young and are too interested in you for my taste. One is too old and a rather odd individual.""I like odd.""I will reconsider her then," she allowed."Are you saying that to make me happy?""No," Rachel grinned. "I admire your instincts. Do you know how soon you will be needing us?""I'm going to stay in town until the Great Hunt. After my stupendous victory, I'll see if I can get to Brazil, so mid-September.""It will take longer to integrate a member ~ the last week of November," she bargained. I really wasn't in the mood to argue. I was too much the boy who was glad to see his primary guardian standing before him. Pamela was by far the most loving and lethal one of the pack. Rachel was my rock. She kept me alive and I helped give her something to live for, even if it was a flawed 'me'."And Wakko, you don't need to give me a piece of your soul to replace Charlotte. What is hers is hers and what is ours is ours. I'll always miss her and I'm okay with that. She was a good friend and a proud compatriot and I loved her. I never had any sisters of the flesh. Mona, Tiger Lily and Charlotte have been the only real family I've had. I will find another sister and I can now accept that.""Is it alright if I still miss her?" I pondered."Of course, Ishara. Will you still be capable of taking my orders when required?""Yes. If I started ignoring your advice, I wouldn't have been worthy of leading someone like Charlotte into battle. I can honor her by letting you do your job.""Thank you. I still worry about you trying to save everyone, but now I'll worry a little less," she confessed."I still plan to do crazy stuff, hey, do you have a daughter?""No.""Want one?""I'm in the final drawing of lots for the Great Hunt," she smiled once more."You could just ask.""My way is more fun. This way I'll be sure you'll obey," she let her eyes sparkle with a mirthful fire."Don't think I'll go easy on you. I plan to win," I pledged."Of course not. Why would you change now?""I'd rather you bust my balls than mock me?" I pouted. "Instead of spending a moving moment, you are cheering me up.""It is my job to look after you, even now," she stroked my neck affectionately."Especially now," I added as I hit the elevator button."Let's catch up with the others. I need to tell Meridian that she's back in the running.""Oh, that is fortunate," I grinned. "Oh, we'll start our mission to Brazil on Thursday, February 12th.""Is there a significance of that date?"I laughed. I put an arm around her shoulder as the doors opened. There were two others Havenstone ladies onboard."Carnival in Rio de Janeiro!" I exulted. "Half a million tourists a day. Two million Brazilians. Everyone wears a mask. What's not to love?""You are so fortunate you waited until you had witnesses around," Rachel groused."Desiree says it's bad for my prestige to be beaten in public," I chortled. "I'm glad you agree.""Maybe we can spar on the mats today when you get off work?""Oh, I'd like to see that," one of the other Amazons remarked. "Weapons or hand-to-hand?""I'll let him use a weapon. I'll use my hands. I want him to think he has a chance," Rachel declared. My arm was still around her shoulder, so I knew she wasn't really pissed."Didn't you kill Ajax?" the other one noted."He tripped over his shoelaces and impaled himself on his own sword," I sighed dramatically.Since the two women looked at one another, then to Rachel, I knew I'd told the lie well."Cáel had an ally shoot a grenade overhead, Ajax died in the confusion, so whatever blow killed him is irrelevant. Cáel beat Ajax with his mind before a single blow was landed. He made his foe fight his battle and that was how Wakko Ishara won," Rachel responded."Like an Amazon," the first one nodded."With balls," I added."An Amazon with balls? I guess you are, but I don't think the testes mattered in that you beat our foe in a matter your ancestors can be proud of," the second one said."Well said," Rachel nodded."Thank you," I shook her hand. "I'm Cáel Wakko Ishara aka Nyilas.""Oh, I'm Wynona of Allatu," she answered. She shook my hand, I ran a finger over her pulse and got her to blush slightly. Allatu was the Goddess of the Underworld in Canaanite mythology and one of the First Houses."Behave," Rachel whispered."Not likely," I whispered back."Did I say something wrong?" Wynona worried."No. Rachel is my moral guardian. So, do you want to go fishing, I mean swimming tomorrow after work, say 5:15?" I inquired."Sure," her smile broadened. "I excel in the water.""Good, maybe you can teach me a thing or two," I answered. The door opened at the lobby and there stood Desiree."Here," Rachel shoved me out the door. "Take him before he fishes himself into more trouble.""I understand," Desiree grumbled. "Come on fisherman. Financial Investigations is working late tonight and we need to pick up Italian food for twenty-two.""Lead and I shall follow," I proclaimed."Why do you call him the 'Fisherman'," Wynona asked Rachel."Fish, barrel, I'll explain it to you on the way to the garage," Rachel sighed. The doors shut and off we all went.{7:10 pm, Wednesday, August 27th ~ 12 Days to go}"Will you still be having dinner with us once you return back to JIKIT?" Europa asked as Lorraine passed me some Cajun rice."Every Monday and Wednesday night and on Fridays early," I grinned."We are going to be spending some time in Doebridge over the Labor Day weekend," Europa griped. "Do you want to come with us and save Aya from retelling her ordeal to yet another band of pre-Amazons?""Aya, do you want me to run interference for you?" I asked."No," she smiled. "I want you to train for the Great Hunt. Aunt Katrina says Elsa is virtually a guarantee to be one of the thirty.""Ugh," I groaned. "That's the cherry on the top of a rather bizarre day.""Was today bad?" Loraine asked."Let me see, for starters I got to use a variety of weird weapons for firearms practice. I had a feeling I was part of a round-robin, the way they rotated their assistance to me. In the elevator, I was with Brielle and her buddy when we had a security drill. The elevator cut off, but the air handler went into overdrive, dropping the temperature. After a quick democratic vote, I lost my shirt to an impromptu fire to stay warm, alive," I chuckled. "Then we cuddled together for warmth. I was about to lose my undershirt and pants when the alert ended.""Security alerts last less than fifteen minutes," Caitlyn noted. "I doubt you were in any danger of freezing to death.""Brielle was under the impression security alerts could last hours, despite my questionable knowledge otherwise from the handbook I'd read. Since she had the seniority, I thought she knew better.""So now you are shirtless," Europe smirked."I had a spare shirt stashed in Katrina's office, but I was required to change during the meeting because we were running late. Oh, and yesterday I forgot to feed some genetically superior white rats at one of our labs. Apparently they gnawed through their cages, broke out and now are in the Manhattan underworld, plotting a rodent rebellion," I related."Oh, that was my idea," Loraine perked up."Do you sit around the table with Katrina thinking up this kind of crap!" I protested."Occasionally," Caitlyn admitted. "Most of those are pure Katrina though.""Glad to know my misery is a family bonding experience.""You should be glad to know we care about you," Europa beamed."Yeah, I'll remember that and once you are casted I'm going to absolutely abuse my authority in some serious payback," I faux-glared at her."I promise you we will make it fun," Aya pledged."You would betray your own sisters?" Caitlyn questioned."Sisters are sisters, Mother, but boon companions are for life," Aya countered."That's cool, Mom," Europa snorted. "We'll always be taller than Aya, and faster.""Only more proof she'll be smarter," Caitlyn shook her head. "So Cáel what happened next?""What makes you think the rest of my day wasn't mundane and boring?""According to Katrina, you are the best stress reliever at Havenstone since they put in the Jacuzzis. With it being open season on you today, I figured your day was one misadventure after another," Caitlyn smiled warmly."Fine, I had to go to Financial Investigations to discuss my expense account in Europe.""That doesn't sound all that exciting," Loraine said."We were in the pool swimming in the classic Amazon style, I swear, sometime I think I should go to work wearing nothing but a trench coat and a smile," I grouched."Did you make any babies?" Aya chirped."No, I can't have that kind of fun with any employees for another twelve more days. Anyway, they were quite cross with me not using their services and let me know for an hour and, thirty-six minutes. After that I had to get a reference physical.""You are as healthy as a horse," Europa neighed."Funny Epona," I sniffed indignantly. "You are a load of laughs, filly. After I had been turned into a prune they made me undress again. There was some nonsense about all the combat I had been in had made me shorter and given me muscle constriction.""That is a good one," Aya nodded. "I'm glad they were being as creative as you are, Atta.""Who is to say that I'm not being the creative one here?" I winked at her."Were your muscles 'constricted'?" Loraine snickered. Europa gave her a thumbs up for joining on the fun."Nope, all my reflexes are in working order and I can still salute on demand," I smiled. "Which was good because after that, I worked through lunch with Acquisitions discussing Khanate plans for Siberia." There was a pause."What was so horrid about that?" Loraine inquired, as if I had been tortured up until that point."We had to do the whole three hour routine on the practice mats. I was pinned grappled and I had something that was strangely reminiscent of a titty-snuggle. I mean, all that skin-tight clothing, close contact and sweaty bodies was murder on my concentration," I confessed."We aren't going to be investing in Siberia, are we?" Aya winked at me."I don't know. I spent three hours saying "I don't know" and "I haven't a clue.""You are good at that," Europa jibed. I flicked a pea at her, bouncing it off her chin. She was getting ready for a spaghetti & meatball counterattack when Caitlyn's cough brought her up short."He is the Head of House Ishara. He can act that way. You are Epona and we are better behaved."Europa stuck her tongue at me, I returned the gesture and this time Caitlyn's cough was aimed at me. She followed that up by rubbing her foot along my shin. I smiled at her, then caught Aya smiling at the both of us. Then I recalled Aya had set the table, damn it."I'll get us dessert," Aya beamed happiness my way. I was thinking about dessert alright, damn that girl.{Rhada Revisited}"I'm home gang," I exhaled. "Ready to go out?" and was promptly shot with a Nerf gun. "What did I do this time?"Timothy and Odette were getting off the sofa. Odette was taking aim while Timothy left his single-shot where he'd been sitting."We are going out. You are not," Timothy grinned. "You have company in the bedroom.""Man, I was looking forward to," then Odette shot me in the stomach with her six shot nerf repeater."You have company," Odette emphasized the 'company' part. To me this implied someone who I couldn't seduce with a few words, maybe get busy for half an hour then go out partying. That could only mean,I opened my door and there lay Rhada, completely naked, hogtied and bound. She had even been gagged. Her look of hate and loathing turned to, something else; part fear and part heartsick yearning. Could Timothy and Odette, really just Timothy, I loved Odette but she had the combat skills of a Tribble. Could Timothy defeat Rhada so thoroughly that she could be so bound?Not likely. I'd been neglecting her, What with being kidnapped, running off to Europe and generally doing my job, I'd neglected her well-defined physique, olive skin and athletic curves. I'd been a fool for letting her waste away while I'd been 'not' earning a paycheck. Hell, I was working too much. I'd played around in college and still managed to graduate with good grades, and it wasn't like I had been hired for my brains."Oh, I've been missing this," I relished her helplessness while rubbing my palms together."Mumph," Rhada protested. It was hard for her to move her body. Her legs were bound above the knee to her shins while her ankles were lashed together and then to the top of her thighs.Her elbows and wrists were tied behind her back, wrists to wrist. The ropes securing her arms crisscrossed above and below her breasts and looped around her neck. She looked tightly secured. A bit too secured. I couldn't see how to un-hog-tie her."Don't you dare go anywhere," I warned Rhada then backed out of the room hurriedly."I suggested the ass plug!" Odette smiled as I turned around. I'd missed that given the shapeliness of her buttock,"I color-coded the ends of the ropes for you. Pull the yellow, then green and then pink and she'll come undone just fine. I put some ointment by the bedside for after. It will help numb the burn and promotes healing without scarring," Timothy patted me on the shoulder. "Now that you've b

La guerra sui mari si sviluppa nell'Adriatico, fra l'Austria-Ungheria, la Francia e il Montenegro, ma anche nel Mare del Nord, dove gli Uboot della Kaiserliche Marine ottengono la loro consacrazione definitiva. Il sommergibile diviene l'arma definitiva della Germania per la prosecuzione della propria guerra navale.Seguimi su Instagram: @laguerragrande_podcastSe vuoi contribuire con una donazione sul conto PayPal: podcastlaguerragrande@gmail.comScritto e condotto da Andrea BassoMontaggio e audio: Andrea BassoFonti dell'episodio:Annuaire de la Marine, 1915Günter Bischof, Ferdinand Karlhofer, Nicole-Melanie Goll, Samuel R. Williamson, ‘Our Weddigen.' On the Construction of the War Hero in the k.u.k. Army.: The ‘Naval Hero' Egon Lerch as an Example, 1914: Austria-Hungary, the Origins, and the First Year of World War I, Univertity of New Orleans Press, 2014Douglas Botting, I sommergibili, Mondadori, 1988 Heiko Brendel, Lovćen, 1914-1918 Online, 2014British Merchant Ships Lost to Enemy Action, Years 1914, 1915, 1916 in date order, Naval History, 2011David Brown, The Grand Fleet: Warship Design and Development 1906–1922, U. S. Naval Institute, 1999Malcolm Brown, The Imperial War Museum Book of the First World War: A Great Conflict Recalled in Previously Unpublished Letters, Diaries, Documents and Memoirs, University of Oklahoma Press, 1993Marc Castel, Fresnel, Sous marins francais Richard Compton-Hall, Submarines at war, 1914–18, Periscope Publishing, 2004J. S. Corbett, Naval Operations. History of the Great War based on Official Documents, Imperial War Museum and Naval & Military Press, 1938Károly Csonkaréti, Marynarka Wojenna Austro-Węgier w I wojnie światowej 1914-1918, Arkadiusz Wingert, 2004Mike Farquharson-Roberts, A History of the Royal Navy: World War I, I.B.Tauris, 2014Robert Gardiner, Randal Gray, Conway's All The World's Fighting Ships 1906–1921, Conway Maritime Press, 1985R. Gibson, M. Prendergast, The German Submarine War, 1914–1918, Naval Institute Press, 2003James Goldrick, Before Jutland: The Naval War in Northern European Waters, August 1914 – February 1915, U. S. Naval Institute, 2015Paul G. Halpern, La grande guerra nel Mediterraneo, LEG, 2008Paul G. Halpern, Mediterranean Theater, Naval Operations, 1914-1918 Online, 2016Peter Hart, La grande storia della Prima Guerra Mondiale, Newton & Compton, 2013Guðmundur Helgason, WWI U-boats: KUK U12, German and Austrian U-boats of World War I - Kaiserliche Marine - Uboat.net, 2008David Howarth, Le corazzate, Mondadori, 1988John Jordan, Philippe Caresse, French Battleships of World War One, Seaforth Publishing, 2017Charles Koburger, The Central Powers in the Adriatic, 1914–1918: War in a Narrow Sea, Praeger, 2001Laibacher Zeitung n. 73, 1915Robert Massie, Castles of Steel: Britain, Germany, and the Winning of the Great War at Sea, Jonathan Cape, 2004Erwin Sieche, French Naval Operations, Engagements and Ship Losses in the Adriatic in World War One, 2000Erwin Sieche, The Austro-Hungarian Submarine Force, 2000Anthony Sokol, Naval Strategy in the Adriatic Sea During the World War, U. S. Naval Institute, 1937Anthony Sokol, The Imperial and Royal Austro-Hungarian Navy, U. S. Naval Institute, 1968Spencer Tucker, World War I: The Definitive Encyclopedia and Document Collection, 2014Pierpaolo Zagnoni, Il ritrovamento della torpediniera 88S, Sub 290, Adventures, 2009In copertina: Logan Marshall, Gilbert Parker, Vance Thompson, Philip Gibbs, Illustrazione dell'azione del 22 settembre, in Thrilling stories of the Great War on land and sea, in the air, under the water, 1915

Consultorio bursátil de febrero de 2025 en el que Adrián Godás y Paco Lodeiro respondemos a las preguntas de los oyentes. Las preguntas generales de este mes son sobre alternativas a MyInvestor, buscar una rentabilidad del 6-7% con riesgo bajo, pignorar el patrimonio financiero, la influencia de inversión de la curva de tipos en deuda corporativa, invertir en acciones coreanas desde Interactive Brokers, la situación en la República del Congo, exclusiones de bolsa sin OPA, Deep Research de Open IA y sobre los agentes que realizan coberturas de petróleo y gas. Y las dudas sobre empresas y sectores son sobre invertir en utilities, RWC, Fountaine Pajot, Montage Gold, Evolution Gaming, Ivanhoe y Alphamin, Valaris y Sintana Energy, Tinybuild, cómo comprar oro físico y sobre Adriatic. Patrocinador del programa Paleobull, con código de descuento para los oyentes.

Have you ever dreamed of your own Eat, Pray Love moment? In this captivating episode of our Passport to Love series, we dive into the love story of Jennifer and Marco, who met by chance in a small coffee shop in Croatia. Jennifer, an American backpacker, was traveling the world on her own Eat, Pray, Love journey, when she met Marco, a charming Croatian working in the yachting industry. What started as a casual encounter over coffee quickly blossomed into a romance that would change the course of their lives.Jennifer continued her adventures across the globe, eventually settling in Australia, but her heart kept pulling her back to Marco. After a lot of soul-searching, Jennifer made the life-changing decision not to stay in Australia and instead pursue her relationship with Marco, committing fully to building a future together. Today, the couple co-owns a yacht business in Croatia, Anchor Croatia, splitting their time between the stunning Adriatic coast and the bustling energy of New York City.In this episode, Jennifer shares her journey of love, travel, and the pivotal decisions that led her to a life she never imagined. From falling in love while traveling to building a thriving business together, her story is one of adventure, passion, and following your heart across continents and oceans.Key Takeaways:Jennifer's 6-Month Eat, Pray, Love Adventure. How Jennifer met Marco by chance in a coffee shop in Croatia.Jennifer's decision to leave Australia and pursue her relationship with Marco full-time.How the couple started a successful yacht business in Croatia and now splits their time between two countries.Insights into the lifestyle of living half the year in Croatia and half in New York, balancing love, business, and adventure.If you've ever wondered how travel can lead to unexpected love and life-changing decisions, Jennifer's story will inspire you to embrace the unknown and trust the journey.Thanks To Our Sponsors:Best Day Brewing: All the romantic moments, without the booze. Shop Here.https://transform-with-travel.captivate.fm/bestdaybrewing AndBeyond: Check out their collection of sustainable & luxurious lodges, camps and itineraries at here -> https://transform-with-travel.captivate.fm/andbeyond Check Out Honeymoons here -> https://transform-with-travel.captivate.fm/honeymoon Connect with Jennifer:Instagram: https://instagram.com/anchorcroatia Website: https://www.anchorcroatia.com/ Connect with KellyFollow the Podcast on IG: http://www.instagram.com/transformwithtravel Follow Kelly Tolliday on IG: http://www.instagram.com/kelly.tolliday Transform With Travel Website:

Drs. Desai and Abu Rous discuss the  data, as presented at ASCO 2024, and how it may change the field of treatment for limited stage small Adriatic Studycell lung cancer.

As domestic leagues resume, we deploy the age-old rest vs rust battle in the aftermath of EuroCup.Spain saw a pair of one possession wins further middle the middle of the pack, and a reminder of who resides in the top tier until proved otherwise.Germany saw a clear case of weekend-off benefits vs EuroCup hangover, and a bid for a second straight upset of a top-4 team.Italy saw yet another scrap of an Adriatic derby decided by a single point, as well as a resounding revenge game as an early-season score was settled.Available now, wherever you get your podcasts! Get full access to Bench Units at benchunits.substack.com/subscribe

Coming up on this week's edition of The Spark Weekly. Today we are honoring Holocaust Remembrance Day. It’s a day to reflect on the lives lost, resilience of survivors, and lessons we must never forget. Dr. Mark Glick is the only living child of Polish Holocaust Survivors. and Jennifer N. Sellitti is a lawyer and shipwreck hunter. She is also the author of The Adriatic Affair: A Maritime Hit-And-Run Off the Coast of Nantucket. The book will be released on February 28. The book tells the story of the collision that sane Le Lyonnais and its aftermath. Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

By 281 BC, Rome controlled much of Italy, but the city was still a minor player on the larger Mediterranean scene. That changed when King Pyrrhus of Epirus crossed the Adriatic with a powerful army of Macedonian pikemen and war elephants, setting in motion the toughest war the Romans had ever fought.Patrick's book is now available! Get The Verge: Reformation, Renaissance, and Forty Years that Shook the World in hardcopy, ebook, or audiobook (read by Patrick) here: https://bit.ly/PWverge. And check out Patrick's new podcast The Pursuit of Dadliness! It's all about “Dad Culture,” and Patrick will interview some fascinating guests about everything from tall wooden ships to smoked meats to comfortable sneakers to history, sports, culture, and politics. https://bit.ly/PWtPoDListen to new episodes 1 week early, to exclusive seasons 1 and 2, and to all episodes ad free with Wondery+. Join Wondery+ for exclusives, binges, early access, and ad free listening. Available in the Wondery App https://wondery.app.link/tidesofhistorySee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jennifer N. Sellitti is a lawyer and shipwreck hunter. She is also the author of The Adriatic Affair: A Maritime Hit-And-Run Off the Coast of Nantucket. The book will be released on February 28. The book tells the story of the collision that sane Le Lyonnais and its aftermath. The Le Lyonnais collided with the ship called the Adriatic off the coast of Nantucket in November of 1856. And it's the story of both the collision, how 18 people survived this disaster, and the aftermath of the collision, which actually had some political consequences involving the way shipping regulations in the North Atlantic developed from the mid -19th century as nations were grappling with what happened when two ships from different countries met.” Jennifer spent a decade researching the ship, the people on board, the circumstances of the collision, and the circumstances of people who survived in lifeboats. Some of the research involved divers from her team D/V Tenacious, to locate Le Lyonnais. “So, what we do is we map the historical data to the hang locations, and then we go out with a side scan sonar. We imagine the ocean floor. We spent two years imagining the ocean floor to find potential targets. And then last summer, we went out to dive several targets, and one of them turned out to be the ship that we were looking for, the Le Lyonnais, and we put divers on it to confirm that identification.” Jennifer wrote this book for those who are not familiar with shipwrecks and hopes readers takes away the importance of shipwreck preservation. “I tried to educate readers just on the importance of our maritime history. It's estimated that there are about four million ships on the ocean floor all around the world. We have many, many ships off the east coast of the United States. And each one of those ships really has a story to tell. When you think about what happened to the people on those ships, the stories of the people who lived, the stories of the people who died, there's so much history.” Jennifer will continue exploring the Le Lyonnais, and shipwrecks off the coast of New Jersey and off the coast of Nantucket.Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

Was an RAF Douglas Boston chased over the Adriatic by six strange fireballs only weeks away from the end of the war in Europe? If so, why does the witness who claimed he was onboard the aircraft appear in the squadron records for the month in question?More about UFO sightings in WW2 in Graeme's book UFOs Before Roswell: https://www.amazon.co.uk/dp/B09DN3BV72Book Ryan on CAMEO at: https://bit.ly/3kwz3DOPatreon: http://www.patreon.com/somewhereskiesByMeACoffee: http://www.buymeacoffee.com/UFxzyzHOaQPayPal: Sprague51@hotmail.comDiscord: https://discord.gg/NTkmuwyB4FBluesky: https://bsky.app/profile/ryansprague.bsky.socialTwitter: https://twitter.com/SomewhereSkiesInstagram: https://www.instagram.com/somewhereskiespod/Letterboxd: https://letterboxd.com/Sprague51/Order Ryan's new book: https://a.co/d/4KNQnM4Order Ryan's older book: https://amzn.to/3PmydYCStore: http://tee.pub/lic/ULZAy7IY12URead Ryan's articles at: https://medium.com/@ryan-sprague51Opening Theme Song, "Ephemeral Reign" by Per KiilstofteProduced by LIONSGATECopyright © 2024 Ryan Sprague. All rights reservedSupport this show http://supporter.acast.com/somewhere-in-the-skies. Hosted on Acast. See acast.com/privacy for more information.

This week the boys take to the skies accompanied by David's brother Matthew and a pig man who can fly biplanes! TGMEM tackles their first Studio Ghibli film from the creative mind of Hayao Miyazaki, Porco Rosso. Don't worry, they do discuss the pig's penis and debate if they would eat him. Soar through the clouds of the Adriatic and find out if Porco Rosso is The Greatest Movie Ever Made! Porco Rosso (1992) is directed by Hayao Miyazaki and stars Shūichirō Moriyama, Tokiko Kato, Bunshi Katsura VI, Tsunehiko Kamijô, and Akemi Okamura. Music: “Fractals” by Kyle Casey and White Bat Audio

Robert D. Kaplan discuses his new book "Waste Land: A World in Permanent Crisis" and how we are in a Global Weimar where the planet is running a strange simulation of the Weimar Republic. The world is becoming more interconnected and claustrophobic as Globalization 2.0 pulls us closer together. All three great powers are in decline, but America has the greatest potential to remake itself, and can see a new burst of dynamism under Trump. Israel stands at the heart of this global geopolitical war. Because of urbanization cities will be the principle world stage going forward where crowds, technology, and history will intersect. Watch on BitChute / Brighteon / Rokfin / Rumble / Substack Geopolitics & Empire · Robert Kaplan: Global Weimar, Waste Land, & a World in Permanent Crisis #507 *Support Geopolitics & Empire! Become a Member https://geopoliticsandempire.substack.com Donate https://geopoliticsandempire.com/donations Consult https://geopoliticsandempire.com/consultation **Visit Our Affiliates & Sponsors! Above Phone https://abovephone.com/?above=geopolitics easyDNS (use code GEOPOLITICS for 15% off!) https://easydns.com Escape The Technocracy course (15% discount using link) https://escapethetechnocracy.com/geopolitics PassVult https://passvult.com Sociatates Civis (CitizenHR, CitizenIT, CitizenPL) https://societates-civis.com Wise Wolf Gold https://www.wolfpack.gold/?ref=geopolitics Websites Website https://robertdkaplan.com Waste Land: A World in Permanent Crisis https://www.amazon.com/Waste-Land-World-Permanent-Crisis-ebook/dp/B0D2W1B519 Robert D. Kaplan | The Tragedy of 21st Century Geopolitics https://www.youtube.com/watch?v=rdvuDByLmig Robert Kaplan: China Seeks World Island as Middle East Forges New Architecture https://geopoliticsandempire.com/2023/08/20/kaplan-china-world-island-mideast-architecture About Robert D. Kaplan ROBERT D. KAPLAN is the bestselling author of twenty-three books on foreign affairs and travel translated into many languages, including Waste Land, The Loom of Time, The Tragic Mind, Adriatic, The Revenge of Geography, Asia's Cauldron, The Coming Anarchy, and Balkan Ghosts. He holds the Robert Strausz-Hupé Chair in Geopolitics at the Foreign Policy Research Institute. For three decades he reported on foreign affairs for The Atlantic. He was a member of the Pentagon's Defense Policy Board and the U. S. Navy's Executive Panel. Foreign Policy magazine twice named him one of the world's “Top 100 Global Thinkers.” *Podcast intro music is from the song "The Queens Jig" by "Musicke & Mirth" from their album "Music for Two Lyra Viols": http://musicke-mirth.de/en/recordings.html (available on iTunes or Amazon)

Robert D. Kaplan discuses his new book "Waste Land: A World in Permanent Crisis" and how we are in a Global Weimar where the planet is running a strange simulation of the Weimar Republic. The world is becoming more interconnected and claustrophobic as Globalization 2.0 pulls us closer together. All three great powers are in decline, but America has the greatest potential to remake itself, and can see a new burst of dynamism under Trump. Israel stands at the heart of this global geopolitical war. Because of urbanization cities will be the principle world stage going forward where crowds, technology, and history will intersect. Watch on BitChute / Brighteon / Rokfin / Rumble / Substack Geopolitics & Empire · Robert Kaplan: Global Weimar, Waste Land, & a World in Permanent Crisis #507 *Support Geopolitics & Empire! Become a Member https://geopoliticsandempire.substack.com Donate https://geopoliticsandempire.com/donations Consult https://geopoliticsandempire.com/consultation **Visit Our Affiliates & Sponsors! Above Phone https://abovephone.com/?above=geopolitics easyDNS (use code GEOPOLITICS for 15% off!) https://easydns.com Escape The Technocracy course (15% discount using link) https://escapethetechnocracy.com/geopolitics PassVult https://passvult.com Sociatates Civis (CitizenHR, CitizenIT, CitizenPL) https://societates-civis.com Wise Wolf Gold https://www.wolfpack.gold/?ref=geopolitics Websites Website https://robertdkaplan.com Waste Land: A World in Permanent Crisis https://www.amazon.com/Waste-Land-World-Permanent-Crisis-ebook/dp/B0D2W1B519 Robert D. Kaplan | The Tragedy of 21st Century Geopolitics https://www.youtube.com/watch?v=rdvuDByLmig Robert Kaplan: China Seeks World Island as Middle East Forges New Architecture https://geopoliticsandempire.com/2023/08/20/kaplan-china-world-island-mideast-architecture About Robert D. Kaplan ROBERT D. KAPLAN is the bestselling author of twenty-three books on foreign affairs and travel translated into many languages, including Waste Land, The Loom of Time, The Tragic Mind, Adriatic, The Revenge of Geography, Asia's Cauldron, The Coming Anarchy, and Balkan Ghosts. He holds the Robert Strausz-Hupé Chair in Geopolitics at the Foreign Policy Research Institute. For three decades he reported on foreign affairs for The Atlantic. He was a member of the Pentagon's Defense Policy Board and the U. S. Navy's Executive Panel. Foreign Policy magazine twice named him one of the world's “Top 100 Global Thinkers.” *Podcast intro music is from the song "The Queens Jig" by "Musicke & Mirth" from their album "Music for Two Lyra Viols": http://musicke-mirth.de/en/recordings.html (available on iTunes or Amazon)

  In this Episode of The Thermal, an epic Christmas Day flight that covered most of the eastern Adriatic and 4 countries with a blistering average speed of 160 kmph and a distance of some 1100 kms.  And hitting it hard with a 50 year old glider. Who says you need the latest hot ship to have fantastic gliding adventures. We talk to a pilot who's checking all the boxes.  We also hear from NAV Canada and their concerns about glider traffic conflicting with commercial traffic. We try to unravel how to make uncontrolled airspace safer for everyone.  That's all on Episode   #58 of The Thermal.

On this episode of Unstoppable Mindset we meet and get to talk with Dr. Christine Balarezo. While Christine was born in Peru much of her youth was spent in California and then Connecticut. During her life she has secured various college degrees including a Ph.D. in Political Science from the University of North Texas. She spent ten years working in the field of human trafficking. Later she worked briefly for a nonprofit organization.   Christine was never fully satisfied with both working for other organizations and for working in academia. After her time with a nonprofit she decided to go out on her own. What she realized she was being directed by her inner self to do was to take up the job of more directly helping others. Christine became a spiritual coach and healer. Today as she explains she “helps creative sensitives reconnect to their true soul being by using her intuitive and psychic gifts with practical, multi- and interdisciplinary transcultural knowledge so they can fully shine their light”.   Our conversation touches on many topics including the concepts of spiritual healing, psychic intuition and some of the fears and prejudices around these concepts. I hope you enjoy what Christine has to say. One thread I find both with this conversation as with so many we have had on Unstoppable Mindset is that we all should learn to be more open and curious to things we may not fully understand or embrace.       About the Guest:   Dr. Christine Balarezo is Founder of Christine Balarezo, which offers multidimensional spirituality services for clients around the world. She is an Intuitive Spiritual Coach, Energy Healer, Intuitive Astrologer, and Educator. She helps creative sensitives reconnect to their true soul being by using her intuitive and psychic gifts with practical, multi- and interdisciplinary transcultural knowledge so they can fully shine their light. Christine loves working with diverse groups of people especially those with multidimensional identities and/or overlapping intersectionalities, neurodivergents, HSPs, BIPOC, single parents, immigrants, witches and healers. In a past life, she was a human trafficking scholar with ten years of experience in the field, and with expertise in mixed-methods trafficking and policy research. Christine began her career in academia serving as an Adjunct Professor of Political Science, and a Fulbright Postdoctoral Research Scholar, where she conducted fieldwork across Israel on its human trafficking policy. She also had a brief stint in the nonprofit world supporting national anti-trafficking efforts. As a multicultural Latina and single mother, she is also passionate about mentoring and continues working with vulnerable populations within the mental health, metaphysical, and higher education fields. Christine received her Ph.D. in Political Science from the University of North Texas, and her M.A. in Political Science from the University of South Florida. Christine's goal is to provide practical yet cosmic guidance - balancing the scales, that is - so people can live a life that is true to them and their heart. When she's not helping others or talking about energy, she loves traveling and exploring new places, cooking Peruvian and Asian food, spending time with her college son, walking their two dachshunds, and finding new books to read at the library.   Ways to connect with Dr. Christine:   Email: christine@christinebalarezo.com Join My Newsletter: https://sendfox.com/christinebalarezo Grab a Virtual Coffee & Let's Chat: https://tidycal.com/christinebalarezo/cafecito-connection-chat Website: https://christinebalarezo.com LinkedIn: https://www.linkedin.com/in/christinebalarezo46/ YouTube: https://www.youtube.com/c/ChristineBalarezo Pinterest: https://www.pinterest.com/christinebalarezo       About the Host:   Michael Hingson is a New York Times best-selling author, international lecturer, and Chief Vision Officer for accessiBe. Michael, blind since birth, survived the 9/11 attacks with the help of his guide dog Roselle. This story is the subject of his best-selling book, Thunder Dog.   Michael gives over 100 presentations around the world each year speaking to influential groups such as Exxon Mobile, AT&T, Federal Express, Scripps College, Rutgers University, Children's Hospital, and the American Red Cross just to name a few. He is Ambassador for the National Braille Literacy Campaign for the National Federation of the Blind and also serves as Ambassador for the American Humane Association's 2012 Hero Dog Awards.   https://michaelhingson.com https://www.facebook.com/michael.hingson.author.speaker/ https://twitter.com/mhingson https://www.youtube.com/user/mhingson https://www.linkedin.com/in/michaelhingson/   accessiBe Links https://accessibe.com/ https://www.youtube.com/c/accessiBe https://www.linkedin.com/company/accessibe/mycompany/   https://www.facebook.com/accessibe/       Thanks for listening!   Thanks so much for listening to our podcast! If you enjoyed this episode and think that others could benefit from listening, please share it using the social media buttons on this page. Do you have some feedback or questions about this episode? Leave a comment in the section below!   Subscribe to the podcast   If you would like to get automatic updates of new podcast episodes, you can subscribe to the podcast on Apple Podcasts or Stitcher. You can subscribe in your favorite podcast app. You can also support our podcast through our tip jar https://tips.pinecast.com/jar/unstoppable-mindset .   Leave us an Apple Podcasts review   Ratings and reviews from our listeners are extremely valuable to us and greatly appreciated. They help our podcast rank higher on Apple Podcasts, which exposes our show to more awesome listeners like you. If you have a minute, please leave an honest review on Apple Podcasts.       Transcription Notes:   Michael Hingson ** 00:00 Access Cast and accessiBe Initiative presents Unstoppable Mindset. The podcast where inclusion, diversity and the unexpected meet. Hi, I'm Michael Hingson, Chief Vision Officer for accessiBe and the author of the number one New York Times bestselling book, Thunder dog, the story of a blind man, his guide dog and the triumph of trust. Thanks for joining me on my podcast as we explore our own blinding fears of inclusion unacceptance and our resistance to change. We will discover the idea that no matter the situation, or the people we encounter, our own fears, and prejudices often are our strongest barriers to moving forward. The unstoppable mindset podcast is sponsored by accessiBe, that's a c c e s s i capital B e. Visit www.accessibe.com to learn how you can make your website accessible for persons with disabilities. And to help make the internet fully inclusive by the year 2025. Glad you dropped by we're happy to meet you and to have you here with us.   Michael Hingson ** 01:21 Well, hi and welcome to another episode of unstoppable mindset. Today we have the pleasure of talking with Dr Christine Balarezo and Christine, well, what can I tell you about Christine? She has founded a company called Christine Valery so and she offers multi dimensional spirituality and coaching. And I'm not going to go into it all, because it's more fun to hear it from her than to hear it from me. Anyway, so I'm just going to say, Christine, I really want to welcome you to and thank you for coming on unstoppable mindset.   Dr Christine Belarezo ** 02:00 Thank you so much, Michael. I'm really grateful and excited to be here and to converse with you and simply see wherever we go in this conversation. Well, it'll be fun.   Michael Hingson ** 02:12 And yeah, who knows where we're going to go? It'll it'll be fun. I've got lots of questions I can think of, and I'm sure you have lots of things to say. Let's start with something that should be pretty easy. Tell us about, kind of the early Christine, growing up and so on, and kind of maybe how you got where you are today. But let's start with sort of the the early Christine,   Dr Christine Belarezo ** 02:32 absolutely. So I'm Christine, as many of you know, most people call me this. I was born in Peru to Peruvian parents, but my mom came here when she was 16, to the United States, to Connecticut, specifically, and then she went back to Peru and met my dad. And I was born there during the time of a civil war, and my parents realized that they had wanted to live somewhere else, perhaps maybe with more stability and see a different type of lifestyle. So they first moved to California, and eventually we ended up in Connecticut, and that's where I spent my earlier years. I grew up on the Long Island Sound in Connecticut, where my grandparents had already come beforehand, and they established a restaurant, and that's where I saw my formative years. It was a very different, I think, way of living, because since then, I've moved I also have a twin sister, and it was, again, a different way of for me growing up, perhaps coming from another culture and blending that into where I grew up in, which was predominantly homogenous, so there wasn't too much diversity, and I learned to navigate different types of people and experiences. And long story short, we're speeding it up here in high school, I moved to Florida, which opened up to a completely new culture, different experiences, and my main goal in life was to work with other cultures and other people. And I initially wanted to pursue a line in diplomacy, and that's what I was working towards beforehand. With my background in political science, I really wanted to help people. I really wanted to focus on peace and bringing together, perhaps some type of mediation resolution in countries that experienced a lot of instability, a lot of conflict. But I think life had other plans.   Michael Hingson ** 04:36 That happens a lot, doesn't it? Right? There's   Dr Christine Belarezo ** 04:38 that saying, you know, when you plan something, sometimes God or whatever your beliefs are, there's something that changes your plans. I'm like, Oh, I plan things. So to the T and I realized things are changing, and I'm going to have to also pivot. And I became a single parent. I'm a mom to a beautiful boy when I was still completing my undergraduate. IT career, and so that definitely changed my trajectory. And I know in diplomacy, especially the route that I wanted to go into, it entails a lot of traveling, and sometimes you have to go to locations where you may not be able to bring family. And I knew I didn't want that. So I reformulated, and I'm like, Okay, I'm gonna have to go down a different path. And I realized I may not be able to do that particular line of work, but I still wanted to pursue something to help people, so I pivoted to human rights. And that just opened up because human rights is very broad. It encompasses so many types of groups, so many types of individual rights, civil political liberties, among many other types of perhaps freedoms that we have here in the United States, that we may obviously take for granted, but that are not always present in other countries. And I pursued that path with obviously completing my Bachelor's, my master's, and then my doctorate, and then I changed. I was like, maybe I'll consider academia, and I'll just tell you. Fast forward, many years later, I just started feeling like I couldn't help people in the way that I wanted to because I was not working one on one with people in the way that I felt that I could help them. A lot of it had to do with, maybe more abstract, theoretical types of support and aid. And sometimes I felt like I was lost in that bubble, because academia and sometimes some of the work people do human rights, and it depends, but the line that I was on, it just felt disconnected. I'm like, Where are the people? Why am I? Why am I doing more research and talking about more theory and presenting at conferences? But I don't feel like I'm having the effect that I can to help people navigate in this world. So I went through a period of disillusionment, of feeling very lost, very disconnected and questioning myself. Is this the path that I'm meant to be on? Is this something that my heart is truly connecting to? And I realized it wasn't, and I tried, because of all of the work that I've done, I feel like this was so similar to so many other people that I've spoken to. I'm like, let me see how I can salvage all of this experience, all of my hard work. And I pivoted to the nonprofit in a similar background in human rights, particularly human trafficking, and I tried. I was like, You know what? Let's continue doing what I did in a different way. I just felt like my life was disappearing, and that was not a very positive experience for me, though I learned a lot, really grateful, because something I think that you touch upon in many of your episodes with other folks and even with your own personal story, Michael, is challenges. As humans, we experience a lot of challenges, and it's your attitude that really defines the next step, and I realized this wasn't probably the best, maybe most highlighting or illuminating experience of my life, but I learned something here in this space, and that pivoted me to creating my business eventually, a few years later.   Michael Hingson ** 08:16 And what is the new business about compared to what you'd been doing so   Dr Christine Belarezo ** 08:20 prior, I was really delving into human rights, human trafficking, conflict to an extent too, and working more from that theoretical, academic, research oriented, and also teaching perspective. And I completely crossed the bridge to something very different, and I entered more into the spiritual realm. And this is a broad term, because it encompasses many different elements. Some people say metaphysical. Could say occult, but it was a very non traditional, or maybe alternative field that I never thought that this was something I was going to pivot to, and it connects to a lot of what I experienced in my life, things that I was healing, and that came up for me to heal, especially after leaving that a toxic job, and it provoked a lot of things in such a fast, perhaps accelerated way that made me realize I'm being called to do something on a scale where I might not feel completely comfortable yet, because there was a lot of foreign perhaps feelings or just emotions. When you sit with them like this is new. I kind of felt like a kindergartner, because I was essentially re crafting my identity, who I was and what I was doing. And it's so easy to become attached to who you are, whether, again, it's a political scientist or a teacher, whatever it is, and that's what happened with me. I had to unravel, undo, unlearn a former Christine and completely step into this new role of what my own heart was calling me towards. So my own business focuses on helping people connect to. They really are and learning to trust themselves. And you mentioned this perhaps when we opened up Michael about listening to your intuition of what you're feeling and sensing. And sometimes it's scary, because it may be telling you or bringing up to you, it's time to go. It's time to leave. It's time to end this way of being or doing, existing or identifying, and a lot of times our human selves are like, we're going to hang on.   Michael Hingson ** 10:29 Well, give me a little bit more if you would insight into so exactly, what is it then that that you do now, as opposed to kind of what you were doing before,   Dr Christine Belarezo ** 10:38 well before it was training and helping people in human trafficking, whether it was understanding what the dynamics were, educating students through coursework examples, for example, and now I connect with people generally, one on one through a Coaching environment where I help people transform different obstacles or different experiences that they want to overcome. A lot of it has to do with shining or empowering themselves, showing up as who they who they are, excuse me, and also grappling with anything around fear, whether it's fear of the unknown, fear of change or fear of anything alternative, especially if they have followed a certain paradigm or belief system or religion or a philosophy. And it's like, I feel like I may have gifts in certain areas. Perhaps you can call them psychic gifts, or seeing or sensing things. And I work with people to also harness that. And I do that through through different modalities, intuitive, spiritual coaching when we work one on one, and it's really at the bottom root, it's not therapy. It's a lot about asking questions, because we're focused on solutions and moving forward. It's very forward or future oriented. And we do glean to the past to inform, but we don't stay there. And I incorporate also my own gifts, again, my intuitive and psychic gifts to help people through the questions that I ask, because ultimately, I believe everyone knows and has the answers to what they need and what they know is best for them. It's called our intuition. People know that for many reasons, a lot of times we feel stuck. We don't see things. We may feel like things are unclear, and it's simply getting rid of the noise or chaos around us. So there's a lot of simplifying on so many different layers, and that's what I help people do, because sometimes we have to zero in and it's helpful because other people can see things you don't always see.   Michael Hingson ** 12:42 So how do you how do you do that? How do you get somebody unstuck or open to thinking about doing something or reacting in a different way than they have? A   Dr Christine Belarezo ** 12:54 lot of it takes awareness first. You have to be aware first of maybe any disconnection or what I call similar to what we used to coin in political science, relative deprivation. Sometimes you're seeing things from a certain perspective, where what it is that you want, but where it is that you are existing, or perhaps acknowledging there is some type of distance there. And that's where people maybe fall into a point of suffering, because they're trying to resolve things with what they know, what they've brought in their current belief systems. I call it Life suitcase. Basically everything they know up to that point they're still holding on. And what I do generally, for example, in the first session, I ask a lot of questions about the background, why they're coming to me, what their goals are, what's been going on, to learn a little bit more about who they are as a person, too, but more importantly, where they want to move, what direction generally. And through these questionings that come up a lot of it's intuitive, because once people start talking to me, and even beforehand, I just the best way to explain this is I just get, like a knowing and questions come to me that help unlock some of this for people where they say, Wow, I didn't even realize it about myself. This is what has been holding me back, or this is why I feel scared around this particular issue or being seen. So a lot of it is it happens organically. It happens through me, conversing one on one with people, and all those lines, they connect kind of like connected dot. There's a game. I don't recall a name, but it's a kin of, okay, we have one nugget that has appeared, and we keep following the rest. And I wish I could say this happens in 24 hours, or in a week, where people are like, okay, I'm good to go. We've got it. I'm unstuck. Generally, it happens, I would say, over a period of time, and it depends with everyone. Because, again, awareness is key here. And my point is not to tell people this is what you're doing wrong, or this is what you need to see. Is to help people see that for themselves.   Michael Hingson ** 15:02 Uh, spiritual healing and transformation is something that probably a lot of people look down on. They say that there's nothing really to all that, but leaving what people think aside and maybe, maybe not. But what are the major blocks, or roadblocks, and how do you get past that to say, look, there really is something to be said for this whole idea of you can transform yourself, you can heal yourself. And doing spiritual healing techniques is an IS and ought to be a very important part of what you do.   Dr Christine Belarezo ** 15:40 Thank you for that question. Those were things that I pondered myself, and what I have found that generally, in whatever modality you choose, it's important to know that I and others, in whatever tool you use, it's a facilitation. I'm not here to tell you. I'm going to heal you. I have a magic wand. I'm a fairy godmother from a Disney movie, and poof, you're going to come out of this 100% yield. But what I can tell you is many of the factors, or many of the challenges or blocks, as you name them, that come up for people, they're universal themes around fear, doubt, allowing ourselves to be seen a certain way or to express a certain way. In other words, maybe stepping into what it is that we feel passionate about. And a lot of times I tell people, what makes you excited, what makes you joyful, or what brings up those feelings of, oh, I can't wait to do this. I want to go into this, because that's also telling you a lot about where you might want to go next. And I want to speak a little bit more about the fear and doubt, because, again, depending on many factors, where you've grown up, your family, your society, your culture. And I'll say that broadly speaking, because culture is very multifaceted, multi dimensional, we have a lot of layers that we may be undoing and we may be relearning things, perhaps setting boundaries, speaking up for ourselves, realizing, Wait, I can put my needs first before others, or I can say no, I can also know and realize it's okay to be afraid most of the times, many things that we do, even if we're passionate about them, there could be some fear, like maybe speaking in front of a crowd, You can feel that through your different senses, people get butterflies in their stomach, right? You feel a sensation, or even when you are doing something for the first time that is new, people generally feel it in their body first. So fear is an element. I feel that it's always present. It's about realizing taking that first step forward, no matter how small is, what's going to eventually help dissipate that. And what I have found is not thinking about that long term picture, because a lot of people, and I think it's very perhaps human of us, we want to know the whole picture. If we're leaving a job, we want to know all the steps and what our next job is going to be and what exactly we are going to do. And we want to have that outlined akin to a board game where we want all the answers, because that gives us control. It gives us safety, it provides security, and it allows us to say, well, we can follow the steps because they're already here. And what I've come to realize working with some of the people that I've worked with is many of them are on paths where there aren't steps in front of them, they're doing things that are very different, perhaps different from their family systems, different from their society or culture, or completely different, like I did, where I didn't really have other steps in front of me to follow. There was no manual or rule book. And so a lot of these challenges about overcoming these blocks, they first start with that awareness that I mentioned, and then taking, I call them many action steps. They don't have to be big and they don't have to necessitate planning, and I think that's key, and it's important to remember and in this process itself.   Michael Hingson ** 18:53 So in in dealing with all of this, I know you talk a lot about the whole concept of spiritual connection. What? What exactly is that? And I think maybe the real question is, why is spiritual connection so very important, and how do we really work toward getting there?   Dr Christine Belarezo ** 19:18 You squeezed in three questions. In one,   Michael Hingson ** 19:19 okay,   Dr Christine Belarezo ** 19:21 I love that. I'm the same way. It's like little sub button, you know, something that,   Michael Hingson ** 19:27 what can I say? What can I say? I don't mind it at all.   Dr Christine Belarezo ** 19:31 I think it's a they just they pop out. That's how it works with me, too. I get questions that pop out in very much the same way. And right now, so many changes have been happening, I would say, in such an accelerated speed in many different areas of our lives, and connecting to so many people, whether it's neighbors or clients or friends and family, there's very resonant themes where some excuse me, where people are going through some. In their life, or several something. And a lot of this has to do with coming back to self. And when you mentioned what is spiritual connection, it's simply your connection to something higher, a belief system. Many people call this god. It could be universe, spirit, source, energy, or even your higher self. It varies. I usually just say God for myself, but it's a higher energy source. And realizing sometimes there's a lot of things we as humans want to control. We want to dictate how things will go. We will push and resist. We'll try to fit everything in our suitcase. And when things don't go that way, when the suitcase pops open and we have challenges, the more we resist, the more we suffer, because we're trying to make things happen in our own way. And as humans, we only have a limited ability for certain things to go in that way, except for our mindset, our beliefs, our thoughts, our attitudes. And so the spiritual connection is something bigger you may not always understand, you may not always see, but you you can feel it, and that's something you can cultivate and nurture. And a lot of people have been turning to that, I would say, especially post pandemic, when so many things fell apart, that perhaps is another conversation, but so many things were brought up for people. Am I truly happy doing what I'm doing? Am I in the right relationships? I feel like I'm supposed to be moving on to something else, etc. So many questions came up, and people I found were feeling lost because they were placing a lot of this outside of themselves, perhaps in institutions, in different people. And when those things dissolve, what do you have? And that goes on to the next question is, well, why? Why the spiritual connection? Because the connection we have with God, with the universe, with source, and generally with something divine. We may not always see, but we feel it, something that can never be taken away from us. And I like to relate, relate it almost like an umbilical cord. Think of all of us being in imaginary little bubbles. We all have our own connection to this source, to this divinity that cannot be taken away. And I've been mentioned mentioning this frequently with people. You may have read the book by Victor Frankel in answer for meaning about his experiences in the concentration camps and something he brings about, which you also talk about too, is your attitude towards life, your thoughts, your beliefs, and how that can dramatically change how it is you navigate through life in general, but also challenges. And that's something too with the spiritual connection that can help nurture this too, because you again don't, we don't always have the answers to everything. And the moment where we say, You know what, I give this up to either something higher or I surrender this. More importantly, I'm leaning into faith and hope that things are going to work out in the way that they can. And that's a that brings in a level of acceptance, which doesn't mean that you acknowledge and you say, I'm happy. These challenges are, are are going on in my life, or the others are experiencing this? No, it's simply saying, okay, it is what it is. This has occurred. I can't, can't change it. What can I do moving forward? And for me, one of the best ways that I have found to cultivate or nurture the spiritual connection is by learning how to take time to embrace solitude. And that's again, something that many folks experience with the pandemic. We heard a lot of either anecdotal stories and narratives where people realized, quote, unquote, I found myself, or I realized this is what I wanted in life. Or lot of people saw the duality of the lives they were living before and the lives they were currently living, and how much control a lot of folks had to give up during the pandemic, where they realized I need to make changes, and this is the direction that I feel like I'm being called into and for me, the best way that I saw, perhaps this is what the pandemic. I tend to look for silver linings in hardships and challenges, so in reflection to the pandemic. For instance, one of the things that I saw, that it brought to all of us was how to lean into solitude, how not to be afraid of your own self, your own fears or things that are changing.   Michael Hingson ** 24:25 You know, you said something interesting about people wanting to control everything and they can't. Why can't they so? And that's an interesting discussion. You could you could immediately say, Well, what about things like the pandemic? We didn't have control over the pandemic. And, yeah, that's true. We didn't have control over the pandemic happening. But like with anything, what we do have control over is how we deal with things like the pandemic. So in in terms of that, what can we learn to have better control over the things that occur in our lives, or or, can we   Dr Christine Belarezo ** 25:14 That's a big question, and I do think we can find safety and security in ways or different things we can control, namely, again, what's within us. Think about our circle or bubble of influence, and a lot of it pertains to ourselves, how we react, how we view things right, like putting on maybe a different shirt, some people feel like when they wear something, a certain something, it feels different, and they may feel more confident or vibrant. Maybe it's the material. It honestly doesn't matter, but the way that we try to control things, it all relates down to safety and security. And I feel like the pandemic really blew that out of the waters for so many people, because, again, things just happen that we may not even understand fully. And for me, my own personal belief, I do believe in an afterlife, and I do believe that when our physical bodies end here, we continue on in Adriatic form. And so some people, we may not understand that until that time. We may never understand it, but so many things happen so quickly that we're forced to confront a lot of things that may have been left untouched unseen. That's why there was a lot of healing that came up for people, generally and individually around so many topics, and what I've told folks repeatedly, and also what I've learned my own self, because I didn't come into this world thinking, You know what? I don't need to react to this. I have to learn this too as a human. A lot of this has to do with, again, how we approach things, and that can be something that's difficult to learn because we're unlearning different behaviors that were inculcated from our own family systems, from the way we've grown up, from society and the way we navigated and many of us tapping in to these different issues or problems that have come up. We're adults. I never questioned this when I was five years old, I didn't question, Should I be responsive or reactive at this time? Why am I losing control over this? That's why it's beautiful. Children have a different way of approaching things. If something doesn't work, they may express it through their emotions, right? Tantrums? That's one way they express this energetically. Then they go about like, two minutes later, playing they carry on with adults. We tend to hold on to that and maybe perhaps over identify with some of these things that are not controllable.   Michael Hingson ** 27:53 Well. The other part about it is that as we are dealing with things that happened to us. It seems to be that we can learn to be better prepared for things to happen to us. And what I'm kind of saying about that is all right, so let's take the pandemic. We didn't predict it. Probably couldn't predict it. Well, I'm pretty sure we couldn't predict it, but so many people just were going around trying to figure out what to do with themselves. The government wasn't helping with that. For a while, we got a lot of mixed messages, but at the same time, what comes to mind is that we could learn more about being able to face unexpected situations. I'm hesitant to use the word control, but we certainly but we really can learn to control how we deal with them, but we don't learn and and have been, in a sense, spoiled, and don't learn how to deal with things that we don't expect to happen. And the result of that is that, because we don't learn anything or give thought to it when something happens, then we don't have, or we haven't created, the tools to deal with it. Does that make sense?   Dr Christine Belarezo ** 29:29 Absolutely, and I will say I agree with all the points that you made, but there are many people that have pivoted and were able sure to change, or perhaps to move with the ways, with the pandemic as a prime example, because they've experienced a lot of different changes in their own life, whether it was growing up in a dysfunctional home or simply maybe moving a lot, or changing schools, or whatever it is that entailed, it's time to adapt to a new way, to a new environment, perhaps to new people. Systems and institutions. So I heard from some folks that this pandemic, for many of them, they embraced it, especially maybe people that were more introverted or that really value that solitude. They really realized it's time for me to go out on my own, maybe work for myself or do things differently, because it created a massive shift in movement around how people work and interrelate   Michael Hingson ** 30:24 well. And I think you're absolutely right. I think it's important that that we do more of that, and we we tend to fear, and we have allowed fear as an entity mostly to overwhelm us, or, as I put it, blind us, or paralyze us, whatever word you want to use, but overwhelm. And so when something happens that causes a fear reaction, we tend not to be able to face it very well, because we've never learned how to harness that fear and use it in a positive way, and I've talked about it before on this podcast, that that was one of the things that I was able to deal with on September 11, because I learned what to do in the case of an emergency, and it created a mindset within me that said, when Something did happen, okay, you know what the options are. Now assess your situation and then deal with the appropriate option based on the situation. Well, there are actually lots of options, because the situation was, there was fire in the building, but the fire wasn't anywhere near us. I knew that because my dog, my guide dog, Roselle, was giving absolutely no indication that she felt fear. And dogs have, I do believe, a much greater sense of some things than people do, and if she had sensed anything that caused her to be concerned, I would know it well she wasn't, which told me that whatever was going on wasn't such an imminent emergency that we couldn't evacuate in an orderly and calm way. And so I worked to get other people in the office calm and got them to the stairs. I didn't a colleague, David Frank did, but David was pretty worried and scared. And in fact, at one point, when I kept saying, slow down, don't panic, he said, You don't understand. You can't see what's going on outside. The problem was that David wasn't seeing what was going on inside, namely the dog that wasn't reacting. And I knew the dog, and I knew that that was part of my world that gave me information that I could use. If Roselle had been acting differently, we would have done things differently, but she wasn't well, so guests got to the stairs, and David and I went to the stairs, and we started down, and we went downstairs. But the bottom line is that it was because I had taken time in advance to prepare and didn't rely on reading signs and other things, that, as I said, it created a mindset. And I think that more often than not, we collectively as people, can learn how to deal with fear in a different way than we do, and that we can use fear as a tool to help heighten our senses, focus us and not overwhelm us and create a situation where we can't make decisions.   Dr Christine Belarezo ** 33:33 Ditto. I loved your example, and I remember reading that and also hearing that about you and Roselle, when you were waiting and kind of feeling into results response, and that was your indicator of like, Okay, do we have anything to be alarmed or not? And that's the same. And I agree with you about animals, they have a high incense, I'll just say their own intuition, but also internal alarm rating that you can sense how animals behave a lot and see what's going on, because they pick up a lot of things, and we don't for so many, for so many reasons. And practicing this fear is key, knowing what you do and how you navigate the world, preparing yourself right, looking for emergency exits, knowing the layout, etc. That's one such way. And in certain circumstances, I think we can prepare to an extent, right? That's one amazing example, if you are traveling, if you're on the plane, if you're in a hotel or in your own home, you can prepare certain things, like safety procedures, making sure you have alternative ways to enter your home if you get locked out, whatever it is. And I think to an extent, we can prepare for certain situations. We see that with natural disasters, right? We can learn a lot from historical events or different types of conflicts. Yeah. But sometimes there's things that happen in our life that we may not always know how to prepare, and a lot of this taps into the emotional response. And something that I have found too is sometimes over preparing for things can induce anxiety in people, because it may provoke fears of, well, wait. What if this happens? And it's not so much about identifying with that potential situation or event that could happen, but simply having some, maybe some type of contingency plan or a backup plan where you can say, how would I approach this? Because when unexpected things happen in our lives, whether it's an unexpected relationship loss or grief that pops up a memory or even an event like you experienced with September 11. We may not always appear or know how to respond, even if we plan for it, but I love the example you gave, because it's an excellent, excellent way of practicing this. We can simply practice and lean into some of the fears by doing a little bit every day, and some may call it a form of exposure therapy. But the more we practice with the unknown, with changes, with navigating things that come in our life, I think the more it gives us that sense of empowerment and also perhaps a calm inner confidence, like, hey, whatever comes our way, we'll be able to navigate this.   Michael Hingson ** 36:24 What I think is is really the issue is that it isn't necessarily planning for every contingency that that is difficult at best anyway, because there are so many contingencies that we don't necessarily know about, but we can learn to know ourselves. And we can learn to say, Okay, I observe this happening. And this is the kind of thing that can happen in an instant, if we work toward it, something does happen, and because we have learned to know ourselves, we've learned to know that we don't need to be afraid to the point where we can't make decisions. We've taught ourselves to be able to make positive or make some sort of decision. By observing those are things that if, if we teach ourselves how to do it, we can learn to very quickly, make the decision that would be best for us. And of course, part of that has to do with learning to listen to our inner selves. And I know one of the things that you talk about is people learning to interpret and understand their own psychic gifts. So how do people learn? Or how can we teach people to learn, to be able to harness and tap into their own intuitive and psychic gifts?   Dr Christine Belarezo ** 37:59 That's, I think, such a fascinating question. And I it repeatedly comes up where so many people now are being put in situations that provoke or prompt this question. Because a lot of people we know and we feel it, that's the thing. It's another sense many people are leaning into now, is what's coming up in their body. It's almost when you meet someone. This is the best example of how you can tap into some of these intuitive and psychic gifts that everyone has, but some people choose not to nurture for many reasons, including fear. But ever meet someone, and it's just their presence, which is, you could say energy, but it's just the presence of a person, whether it's their voice, or when you shake hands with someone, or just being in their proximate vicinity, you may feel off. You may feel certain, certain something is not quite right, and a lot of people have mentioned in so many various circumstances, something feels off about that person. I can't put my finger on it, but I just don't feel comfortable. Or likewise, people come into a room and sometimes they're so full of vitality and life, and you just feel uplifted and energized. And we get certain sensations in different ways that everyone receives them. And that's the first point of our intuitive and psychic gifts, is realizing I'm feeling something. But many people, they're like, Nah, that can be right, or they just count it, or they dismiss it, as I'll say, especially with what I call red flags, right? When you feel something is off, or you're like, I'm not really sure this interaction is best for me or this job, or whatever the circumstance, it's only in retrospect. People are like. I knew it. I felt it. I felt the science. Because we don't see something come up in our inner mind where it tells us, okay, this computer is registering. This person is XYZ. We feel it. So the first step is. Really harnessing your gifts. For those that are just embracing them, they're popping up, or you're wanting to strengthen this is to start paying attention to these moments and to trust what you're feeling. A lot of times, I always suggest to people write them down, whether it's in your phone, in some type of computer application, or you can write it in a way that helps you, or you can a lot of you know what's interesting? I connect to a lot of people that like using video recorders, and they record. You know how some people like to express through journaling, right through words now, and that's another powerful way. But the point here is to take account and to start becoming aware of all those different instances where you may have discounted yourself, and more than likely, the majority of those times you were right, you had some type of feeling where you felt something was off, and that's one of the first things you have to become aware of that, because there's a level of trust that then comes in. Many people don't trust themselves. Or, like, No, this can't be right. Or they say, quote, unquote, I'm crazy, or I'm seeing things, or I'm making things up, or it's just me. Everyone likes this person, or this is a great work environment. And then later on, they're like, I knew something was off. So it takes practice, which you infer of right with leaning into fear. It's the same way with your psychic and intuitive gifts, and we have to practice that continuously. It's a muscle whenever you are Go ahead. No, go ahead. Oh, whenever we are experiencing those moments, it's important to say, Okay, what's coming up for me? Yeah, and a lot of different emotions, and this can stem, again, from your own personal, lived experiences, maybe growing up where people discounted what you said. You weren't allowed to speak or communicate or express yourself in a certain way. Maybe you were invalidated, or people subjugated you to a certain way of being. There's so many different circumstances that I found, but a lot of the stems from earlier parts of our lives, and we're honing this too, and that's just one part of trusting yourself. And for me, I take a very practical approach, because the more I've leaned into trusting myself in my own intuition, and we've all received the psychic messages very differently, too. That's something else very briefly to say, some people may just know things or send things, and that's clear cognizance or clear sentience, or they may see things visually or through dreams, clairvoyance, for example. And so there's different extra sensory ways that these messages come through. And a lot of times I'll say again, like I've said, we feel it in our body first, and it's not something we should intellectualize or something that you can try to analyze. Yeah.   Michael Hingson ** 42:51 And what I was going to react to was the fact that you, you referred to it as a muscle, and it is, and I think it's important that people think about it in that way. My favorite example, and I've used it lots, I hope people aren't getting too bored with it, is trivial pursuit, which is a fun game, and I think of so many times I've played it with people, and I've been a victim of it, and others have been as well. A question is asked, an answer pops into our head, and then we think, no, it can't be that easy. And we think about it and we give a different answer, and invariably, the answer that we originally thought of was the right answer. Our inner selves knows a lot more than we give it credit for, and by practicing to listen to it, I think we all can benefit a great deal, but we do really have to practice and listen to it, because I think that it won't steer us wrong, although I think a lot of people will poo poo that, but it is, it is absolutely true, and there are so many examples of it, so I think it is important, and it's Part of what I put in my new book that's coming out called Live like a guide dog, true stories from a blind man and his dogs about being brave, overcoming adversity and walking in faith. It's all about learning to deal with fear and learning to listen to ourselves and learning not to second guess, but really learn to know more than we do and we can.   Dr Christine Belarezo ** 44:29 Oh, you just beautifully packaged that that could be like the little bow or ticket on a gift. I think you summed it up perfectly. And just to reference Roselle during your time when you are working at the World Trade Center, and even now with your guide dog and any animal in particular, you'll notice that, how many times have you seen a dog or an animal or felt it doubt themselves? I've never because I have two wiener dogs, and you may have heard them, hopefully not loudly. You have two wiener. Dogs. Here dachshunds. I   Michael Hingson ** 45:01 was listening for them. I haven't heard the doxies.   Dr Christine Belarezo ** 45:04 I've never in my life thought, wow, he or she second guessed themselves. They don't need to go to the bathroom. Or if they bark for a reason, because animals are so attuned to different we'll say frequencies like a radio than we are. And again, many stories around how animals will bark at certain people or see things we don't. And brings to mind, they're not second guessing themselves. They know exactly what they've seen, and they will stay very fervent in that position, whether it's barking or they're like, hey, I need to go out, or whatever it is. And they'll let you know, similar to what you brought up with Rosella and how she didn't indicate any fears, which help you tune in and say, Okay, we're good right now at this time. So in the same vein, we can learn a lot from animals. And it seems like your book is tapping exactly into this where animals, they just do it. They don't themselves, they don't question themselves, they don't ask the next dog over. Hey, did you see what I see   Michael Hingson ** 46:02 they don't do, what if they don't? And   Dr Christine Belarezo ** 46:06 that's the beauty that we can learn from from other creatures around this, but also to ourselves. And again, it's just practicing. And this is probably the most boring, unglamorous aspect of this work that I do, because people tend to see it in perhaps a particular way. When you talk about this field of spirituality and psychics and intuition, people see it a certain way, and it's really not this is the boring work of you got to trust yourself first, because if you are receiving those intuitive messages and you don't trust that, there's going to be no one else you can listen to them, but what if they're deceiving you? You got to trust what it is that you're feeling and what's coming up to you, and you've said it, it never leads you astray.   Michael Hingson ** 46:52 As I said, animals don't do what if. But make no mistake, they learn. So there are so many examples of somebody being in a situation like family in a in a building and it catches fire, and the animal comes and it bothers people, until they pay attention and it gets them out. The animal didn't do a well, what if this building catches on fire? What am I going to do? The animal does learn, however, how to move around their place. That's one example. The bottom line is, we can all learn those same sorts of things, and we do have the extra gift of being able to do what if, but we need to learn how to use that too. And again, the best thing about what if is that we learn to build that muscle, that mental muscle, and learn how to know ourselves better so that we can deal with situations that come up. And although not every situation will be the same, and we may not have predicted a particular situation, we can learn well enough to have a pretty good idea of how to deal with most things that come into our lives if we choose to.   Dr Christine Belarezo ** 48:07 I agree. That resonates so much. I always like to say we have our own sniffers, kind of like dogs, because their sense of smell is so acute, and some I would imagine breeds, especially carriers. I'm not a dog expert, but this is just from my experience, and what I've read, they have an even greater sense of smell, where they can send things that we can't. And to your example about, you know, a dog that maybe awakens the family, or even cats or any other animals. I've read so many accounts because I'm an animal lover as well, and I'm just fascinated by they don't question things. They follow their senses. And for many reasons, I feel like animals are also like our own angels, our own guardian angels. They help us in many ways, and we can learn so much like they do, because they adapt. They're super intelligent creatures, and I speak for many different types of creatures, rodents, birds, could be reptiles, dogs and those in the wild that we make there was ways that we can also start practicing and adapting to having that keen sense of knowing who you are. And perhaps that's something people are learning, especially post pandemic, is who am I? And connecting to yourself through those moments of solitude, but also in your surroundings, that's it helps you keep in touch with what's going on, like your own antenna.   Michael Hingson ** 49:33 Well, there's, there is a lot we can learn and hopefully live like a guide dog will help people think about that a little bit more and maybe not fear so many things. Or, you know, another aspect of it is we've got some people who just say, Trust me, I know what's best. Just listen to me. You don't have to worry about it. That never works. And what we really need to do is. Is to not just trust, but make sure that somebody earns our trust, and we really take the time to think that we've really analyzed what they say, and then we can trust perhaps. But even then, it does go both ways, but it is a it is a challenge. Well, tell me something that people don't know about you, just to change the subject.   Dr Christine Belarezo ** 50:30 Wow. You know, I've asked myself this question, and   Michael Hingson ** 50:33 you're still trying to figure out what what you don't know about you, right?   Dr Christine Belarezo ** 50:38 I think that's an ever longing journey or quest. And I think something folks may not know about me is how much I really like to learn. I'm generally a very curious person, and I love asking questions to people. Things pop up and things like sometimes when I speak, it could lead, it could appear or feel like I'm going off a tangent. That's because I get so many things that pop up in my head. I'm like, Oh, this is fascinating. And I can really go down a hole in trying to learn, perhaps over consume or simply engage with someone or something, whether it's a topic, a theme, or something I'm really passionate about, until I know all facets. And when I say all facets, obviously it's not going to happen, because there's something you can always keep learning. Yeah, so simply learn to lean into that, because I'm a lifelong learner, and I've always considered myself like a student in life, a traveler in life and through the world, and I constantly learn new things, and some people when they either sense being in my energy, or if they see me, they judge, because I can be quiet, but that's because I'm observing first, and I'm someone that likes to observe and kind of get a feel. Would this person be open to talking? Do they like to engage? So that's just something that most people don't know about me. It's really easy based on many assumptions, whether it's through personal experiences or maybe something people see in themselves to make those judgments. But I'm a questioner. I just question I love asking people questions about themselves, what, why they do, what they do, what led them to this? And more questions pop up, so it's infinite. Well,   Michael Hingson ** 52:24 that's there's nothing wrong with that curiosity, I think is a good thing, and I love being curious, and I wish more of us would have been taught more about being curious and not discouraged as children, which happens so often. But I think the curiosity is a very important thing to do. So I'm glad you like that, and I'm glad that you talk about that. What kind of advice might you have for others who want to make a big change in their life?   Dr Christine Belarezo ** 52:53 Don't overthink it, just do it. And I also want to preface this, perhaps a mini disclaimer here, obviously, make sure your basic needs are taken care of. You know, like paying your bills and things around those elements. But when it comes to making a change, I find that so many people, and I say this particularly from personal experience, we may lean into it. We may take time. It may be years. I'll just tell you my leap from academia into doing what I am now. I received just knowings just guidance. It's time to end your time here, similar to yours when you left your position at the World Trade Center and you left that career to start speaking, and I've received messages like Diana ignored it, and I took a lot of time. We're talking more than a decade. I'm like, Nope, I'm going to keep pursuing this. So I would say, when you feel something, explore it, and don't be afraid to take action. That doesn't mean, okay, I'm going to quit my job the next day. Can mean maybe it's time to update my resume or CV. Maybe it's time to reconnect to my network and start exploring new opportunities, or hey, that event is calling to me about maybe basketball popped up in my head, or sports, or whatever it is. Take action. Don't put it on pause. Don't wait. Don't say another day, because we tend to analyze things, and then that wheel is fomenting, perhaps of discontent or unhappiness or whatever it is.   Michael Hingson ** 54:32 Yeah, I think again, you're right. You can't, you shouldn't overthink. And if you think about things in the right way and analyze it, you can come to the right decision. And that's really what you're you're looking to do, which is as good as it gets, and that's important to do. Well, tell me, if people tell me a little bit about you and your business. So how do you meet people? How do you reach out to people? How do they find you? And so on.   Dr Christine Belarezo ** 55:05 So I encountered and connected to clients in so many ways, usually in unusual ways, where I'm shopping, maybe at the market, I'm reaching for a fruit and someone's like, hi, I don't know them. And then they start telling me about themselves or life story, and next thing you know, I'm still with the pair in my hand 30 minutes later, and you're like, what do you do? And I let them know, like, wow. I'm like, yeah. And so I meet people in unusual circumstances like that, where I'm just going about my routine other ways, is through connecting one on one, like coffee chats, and that's not usually my main intention. One of my values is connecting and creating bridges with people. I simply like connecting and asking questions, getting to know people, and supporting other people. And many times, folks are interested in what I do, and that's one way that I've gotten clients. I also have a YouTube channel where I talk about astrology, spiritual topics, also real life, everyday topics, because I'm a practical person, and it's important to be grounded in this world and not just completely think my head is in a certain cloud or on, existing on whatever dimension you feel you may be existing on. Very practical here, because we're all here to contribute in some facet, our own lights in this world. So YouTube is another way. I've met people LinkedIn too. You may have experienced this on LinkedIn. I'm sure many folks have where you've had people reach out, whether it's cold calls, I've had people reach out to me where we have no related work, but they may be trying to sell me something, and I've gotten clients in that way. So I don't do traditional forms of marketing. I'm someone that really values creating genuine relationships, rather than something transactional. I hope and try to create, maybe you could say, like a friendship, family, type of connection with people, because trust is really important in the line of work that I do, there are a lot of charlatans, like in many other fields, but I would say more so in this field, and that's why, going back to some of the really great questions you asked and the responses and examples you gave, it's important to trust yourself when you meet. That's why I like offering people the opportunity to engage in video calls with me, because if we don't connect, if you you're not feeling it, I don't personalize it. Um, to me, I think, Okay, I have one new friend that I know in this network. Good luck. Maybe I can offer you someone else that does something that you may connect to, sure. Well,   Michael Hingson ** 57:38 if people want to reach out to you. How do they do that? They   Dr Christine Belarezo ** 57:42 can email me, Troy, provide my email or yes please, it's and spell it out. Okay, it's Christine. I'll spell it in a sec. It's Christina @Christine Balarezo.com so it's C, H, R, as in Robert I S as in Sam T, as in Tom I N as in Nancy E. At, what is that? Called the ampersand?   58:15 No, at, at,   Dr Christine Belarezo ** 58:17 you have it? Christine, again, C, H, R, i, s, t, I, N, E. Valero, so B, as in boy, a, l, a, r, e, Z, as in zebra, o.com, that's one way, email, YouTube channel, my first and last name, Christine valarso through my website, same christineballarso.com Those are many ways to connect with me, and I offer opportunity to connect in one on one chats too.   Michael Hingson ** 58:56 Well. I hope people will reach out. This has been very insightful and very useful, and I hope that it gives people a little bit different slant on some of the things that they may be thinking or hearing within themselves, and that they'll maybe listen a little bit better. So I hope that will happen. And I want to thank you for taking the time to be with us today. I'd like to thank all of you for listening to us. We really appreciate your time. I'd love it if you'd give us a five star rating wherever you're listening to unstoppable mindset. And if you know anyone who ought to come on our podcast, we'd love to hear from you, and Christine for you as well. If you know anyone we're always looking for for guests. And so I hope that that you all will do that, and again, wherever you are, please give us a five star rating. So thank you very much for listening, and we will be back in a little while with another episode of unstoppable mindset. And you can reach out to me, and I'd love it if you would.  you can email me Michael h i@accessibe.com that's m, I C H, A, E, L, H, I at accessibe, A, C, C, E, S, S, I b, e.com, or go to our podcast page, w, w, w, dot Michael hinkson.com/podcast and Michael Hinkson is m, I C H, A, E, L, H, I N, G, s, O n.com/podcast so once more, Christine, thanks very much for being here, and we really appreciate your time.   Dr Christine Belarezo ** 1:00:28 Thank you so much. It was an absolute pleasure. Thank you all great.   **Michael Hingson ** 1:00:37 You have been listening to the Unstoppable Mindset podcast. Thanks for dropping by. I hope that you'll join us again next week, and in future weeks for upcoming episodes. To subscribe to our podcast and to learn about upcoming episodes, please visit www dot Michael hingson.com slash podcast. Michael Hingson is spelled m i c h a e l h i n g s o n. While you're on the site., please use the form there to recommend people who we ought to interview in upcoming editions of the show. And also, we ask you and urge you to invite your friends to join us in the future. If you know of any one or any organization needing a speaker for an event, please email me at speaker at Michael hingson.com. I appreciate it very much. To learn more about the concept of blinded by fear, please visit www dot Michael hingson.com forward slash blinded by fear and while you're there, feel free to pick up a copy of my free eBook entitled blinded by fear. The unstoppable mindset podcast is provided by access cast an initiative of accessiBe and is sponsored by accessiBe. Please visit www.accessibe.com . AccessiBe is spelled a c c e s s i b e. There you can learn all about how you can make your website inclusive for all persons with disabilities and how you can help make the internet fully inclusive by 2025. Thanks again for Listening. Please come back and visit us again next week.

Melvyn Bragg and guests discuss the remarkable rise of Venice in the eastern Mediterranean. Unlike other Italian cities of the early medieval period, Venice had not been settled during the Roman Empire. Rather, it was a refuge for those fleeing unrest after the fall of Rome who settled on these boggy islands on a lagoon and developed into a power that ran an empire from mainland Italy, down the Adriatic coast, across the Peloponnese to Crete and Cyprus, past Constantinople and into the Black Sea. This was a city without walls, just one of the surprises for visitors who marvelled at the stability and influence of Venice right up to the 17th Century when the Ottomans, Spain, France and the Hapsburgs were to prove too much especially with trade shifting to the Atlantic.With Maartje van Gelder Professor in Early Modern History at the University of AmsterdamStephen Bowd Professor of Early Modern History at the University of EdinburghAndGeorg Christ Senior Lecturer in Medieval and Early Modern History at the University of ManchesterProducer: Simon TillotsonReading list:Michel Balard and Christian Buchet (eds.), The Sea in History: The Medieval World (Boydell & Brewer, 2017), especially ‘The Naval Power of Venice in the Eastern Mediterranean' by Ruthy GertwagenStephen D. Bowd, Venice's Most Loyal City: Civic Identity in Renaissance Brescia (Harward University Press, 2010)Frederic Chapin Lane, Venice: A Maritime Republic (Johns Hopkins University Press, 1973)Georg Christ and Franz-Julius Morche (eds.), Cultures of Empire: Rethinking Venetian rule 1400–1700: Essays in Honour of Benjamin Arbel (Brill, 2020), especially ‘Orating Venice's Empire: Politics and Persuasion in Fifteenth Century Funeral Orations' by Monique O'ConnellEric R. Dursteler, A Companion to Venetian History, 1400-1797 (Brill, 2013), especially ‘Venice's Maritime Empire in the Early Modern Period' by Benjamin ArbelIain Fenlon, The Ceremonial City: History, Memory and Myth in Renaissance Venice (Yale University Press, 2007)Joanne M. Ferraro, Venice: History of the Floating City (Cambridge University Press, 2012)Maria Fusaro, Political Economies of Empire: The Decline of Venice and the Rise of England 1450-1700 (Cambridge University Press, 2015)Maartje van Gelder, Trading Places: The Netherlandish Merchant Community in Early Modern Venice, 1590-1650 (Brill, 2009)Deborah Howard, The Architectural History of Venice (Yale University Press, 2004)Kristin L. Huffman (ed.), A View of Venice: Portrait of a Renaissance City (Duke University Press, 2024) Peter Humfrey, Venice and the Veneto: Artistic Centers of the Italian Renaissance (Cambridge University Press, 2008)John Jeffries Martin and Dennis Romano (eds.), Venice Reconsidered: The History and Civilization of an Italian City-State, 1297-1797 (Johns Hopkins University Press, 2000)Erin Maglaque, Venice's Intimate Empire: Family Life and Scholarship in the Renaissance Mediterranean (Cornell University Press, 2018)Michael E Mallett and John Rigby Hale, The Military Organization of a Renaissance State Venice, c.1400 to 1617 (Cambridge University Press, 1984)William Hardy McNeill, Venice: The Hinge of Europe (The University of Chicago Press, 1974)Jan Morris, The Venetian Empire: A Sea Voyage (Faber & Faber, 1980)Monique O'Connell, Men of Empire: Power and Negotiation in Venice's Maritime State (Johns Hopkins University Press, 2009)Dennis Romano, Venice: The Remarkable History of the Lagoon City (Oxford University Press, 2023)David Rosand, Myths of Venice: The Figuration of a State (University of North Carolina Press, 2001)David Sanderson Chambers, The Imperial Age of Venice, 1380-1580 (Thames and Hudson, 1970) Sandra Toffolo, Describing the City, Describing the State: Representations of Venice and the Venetian Terraferma in the Renaissance (Brill, 2020)In Our Time is a BBC Studios Audio Production .

Melvyn Bragg and guests discuss the remarkable rise of Venice in the eastern Mediterranean. Unlike other Italian cities of the early medieval period, Venice had not been settled during the Roman Empire. Rather, it was a refuge for those fleeing unrest after the fall of Rome who settled on these boggy islands on a lagoon and developed into a power that ran an empire from mainland Italy, down the Adriatic coast, across the Peloponnese to Crete and Cyprus, past Constantinople and into the Black Sea. This was a city without walls, just one of the surprises for visitors who marvelled at the stability and influence of Venice right up to the 17th Century when the Ottomans, Spain, France and the Hapsburgs were to prove too much especially with trade shifting to the Atlantic.With Maartje van Gelder Professor in Early Modern History at the University of AmsterdamStephen Bowd Professor of Early Modern History at the University of EdinburghAndGeorg Christ Senior Lecturer in Medieval and Early Modern History at the University of ManchesterProducer: Simon TillotsonReading list:Michel Balard and Christian Buchet (eds.), The Sea in History: The Medieval World (Boydell & Brewer, 2017), especially ‘The Naval Power of Venice in the Eastern Mediterranean' by Ruthy GertwagenStephen D. Bowd, Venice's Most Loyal City: Civic Identity in Renaissance Brescia (Harward University Press, 2010)Frederic Chapin Lane, Venice: A Maritime Republic (Johns Hopkins University Press, 1973)Georg Christ and Franz-Julius Morche (eds.), Cultures of Empire: Rethinking Venetian rule 1400–1700: Essays in Honour of Benjamin Arbel (Brill, 2020), especially ‘Orating Venice's Empire: Politics and Persuasion in Fifteenth Century Funeral Orations' by Monique O'ConnellEric R. Dursteler, A Companion to Venetian History, 1400-1797 (Brill, 2013), especially ‘Venice's Maritime Empire in the Early Modern Period' by Benjamin ArbelIain Fenlon, The Ceremonial City: History, Memory and Myth in Renaissance Venice (Yale University Press, 2007)Joanne M. Ferraro, Venice: History of the Floating City (Cambridge University Press, 2012)Maria Fusaro, Political Economies of Empire: The Decline of Venice and the Rise of England 1450-1700 (Cambridge University Press, 2015)Maartje van Gelder, Trading Places: The Netherlandish Merchant Community in Early Modern Venice, 1590-1650 (Brill, 2009)Deborah Howard, The Architectural History of Venice (Yale University Press, 2004)Kristin L. Huffman (ed.), A View of Venice: Portrait of a Renaissance City (Duke University Press, 2024) Peter Humfrey, Venice and the Veneto: Artistic Centers of the Italian Renaissance (Cambridge University Press, 2008)John Jeffries Martin and Dennis Romano (eds.), Venice Reconsidered: The History and Civilization of an Italian City-State, 1297-1797 (Johns Hopkins University Press, 2000)Erin Maglaque, Venice's Intimate Empire: Family Life and Scholarship in the Renaissance Mediterranean (Cornell University Press, 2018)Michael E Mallett and John Rigby Hale, The Military Organization of a Renaissance State Venice, c.1400 to 1617 (Cambridge University Press, 1984)William Hardy McNeill, Venice: The Hinge of Europe (The University of Chicago Press, 1974)Jan Morris, The Venetian Empire: A Sea Voyage (Faber & Faber, 1980)Monique O'Connell, Men of Empire: Power and Negotiation in Venice's Maritime State (Johns Hopkins University Press, 2009)Dennis Romano, Venice: The Remarkable History of the Lagoon City (Oxford University Press, 2023)David Rosand, Myths of Venice: The Figuration of a State (University of North Carolina Press, 2001)David Sanderson Chambers, The Imperial Age of Venice, 1380-1580 (Thames and Hudson, 1970) Sandra Toffolo, Describing the City, Describing the State: Representations of Venice and the Venetian Terraferma in the Renaissance (Brill, 2020)In Our Time is a BBC Studios Audio Production .

In this episode of “Kimberly's Italy,” co-hosts Kimberly Holcombe and Tommaso Il Favoloso take listeners on a journey through the lesser-known yet captivating regions of Puglia, Basilicata, and Campania, uncovering their unique cultural and geographical features. Puglia: Geography and Features: Nestled between the Adriatic and Ionian seas, Puglia is known for its unique terra rosa soil, abundant olive trees, and renowned wines such as Primitivo and Negroamaro. Cuisine and Climate: The region boasts a vegetable-centric cuisine, diverse climate, and provides a refreshing alternative to the summer heat of Rome. Key Destinations: Highlights include the Gargano promontory, Bari, Ostuni, Lecce, and Santa Maria de Leuca. The iconic trulli houses are now popular accommodations. Basilicata: Historical Context and Terrain: Famous for its mountainous landscape, Basilicata has undergone several name changes, including Lucania under Mussolini. Cultural Highlights: Matera, recognized as a European Capital of Culture in 2019, is famed for its unique sassi cave dwellings. Visitor Tips: Despite lacking an airport, the region offers warm welcomes in its small villages. Potenza is noted for its narrow roads and parking challenges, while Maratea charms visitors with its scenic appeal. Local Wines and Cuisine: The region's wines, Malantrina and Aglianco, pair excellently with local meats and bread. Campania: Cultural Hub: Known for its stunning coastline, Campania is also home to Napoli, the birthplace of pizza and a gateway to Capri, Ischia, Procida, and the Amalfi Coast. Attractions and Planning: Notable sites include the Reggia di Caserta, Pompeii, and Herculaneum. The Amalfi Coast, with its picturesque villages such as Positano and Amalfi, requires careful planning to navigate high prices and crowds. Climate and History: The region benefits from a sunny climate, and south of Salerno you can visit the ancient ruins in Paestum. Coastal Challenges: The islands are full of rocky shores which make for somewhat challenging entries for non-local swimmers! Follow us on Social Media Instagram Facebook  Join Kimberly and Tommaso as they delve into these regions, providing travel tips and cultural insights for an enriching Italian adventure.

Dr. Greg Kalemkerian reviews the latest evidence-based rapid update from the Expert Panel on systemic therapy for small cell lung cancer. He discusses the updated recommendations for patients with limited-stage SCLC based on the ADRIATIC trial, and for patients with relapsed SCLC based on the DeLLphi-301 trial. Dr. Kalemkerian shares insights on what these changes mean for clinicians and patients, and highlights new trials in progress to provide more options for patients diagnosed with SCLC. Read the full rapid update, “Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update” at www.asco.org/thoracic-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02245   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Greg Kalemkerian from the University of Michigan, lead author on, “Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update”. Thank you for being here today, Dr. Kalemkerian. Dr. Greg Kalemkerian: Thank you. Thank you for the invitation. Brittany Harvey: Great. Then, before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Kalemkerian, who has joined us here today, are available online with the publication of the update in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content of this rapid update, Dr. Kalemkerian, what prompted this update to the Systemic Therapy for Small Cell Lung Cancer Guideline, which was previously published in 2023? Dr. Greg Kalemkerian: So even though the original guideline only came out a year ago, the past year we've seen two significant advances in small cell lung cancer with two reports, one in limited stage with the addition of immunotherapy, the other in the addition of a new immunotherapeutic agent in relapsed small cell lung cancer. Brittany Harvey: It's great to have this new data in the small cell lung cancer space. So based on these new changes, what are the updated recommendations from the expert panel? Dr. Greg Kalemkerian: So the first recommendations have to do with patients with limited-stage small cell lung cancer based on the ADRIATIC trial which added consolidation durvalumab for patients who had not had progression after standard chemotherapy and radiotherapy. And this study demonstrated a significant improvement in overall survival with about a 10% improvement in both 2- and 3-year overall survival, up to a 57% overall survival at 3 years for the patients receiving consolidation durvalumab. And based on those findings, we updated the recommendation for the standard treatment for limited-stage small cell lung cancer such that it included the use of consolidation immunotherapy with durvalumab for up to two years in patients who had had no disease progression, and completion of concurrent chemoradiotherapy for limited-stage small cell lung cancer. Of course, those patients would be those who do not have contraindications to the use of immunotherapy. As a corollary to that recommendation, for patients who have poorer performance status, so performance status of 3 or 4, who had had initial treatment perhaps with sequential chemotherapy and radiotherapy, if their performance status improves with their initial treatment, then it would also be reasonable to add consolidation immunotherapy for those patients as long as their performance status maintains improvement and they have no evidence of progression. The other update of the guidelines had to do with patients with relapsed small cell lung cancer and that was based on the DeLLphi-301 trial which was a phase II study looking at the use of tarlatamab, a bispecific T cell engager, binds to both DLL3 and CD3 in order to increase the immune killing of small cell lung cancer cells. So what this study did was it treated patients who had had at least two prior regimens. So this is third-line or beyond was what the population that this study looked at. And the majority of these patients had already had some immune checkpoint therapy. They all had good performance status and it did allow patients with brain metastases to be included in the study. When we look at the patients who received the approved 10 milligram dose of the drug, the response rate was about 40%. Responses were seen in both patients with sensitive and refractory based on the time since their prior treatment and the median duration of response was 10 months, which is much better than anything we've seen before with relapsed small cell lung cancer patients, remembering that all these patients were also third-line or beyond. So based on the results of the DeLLphi-301 trial, we updated two of the recommendations regarding relapsed small cell lung cancer. In the first one, we stated that in patients with relapsed small cell lung cancer with a chemotherapy free interval of less than 90 days, single agent systemic therapy would be considered standard of care, and that the preferred agents would include topotecan, lurbinectedin, or, now, tarlatamab. We did mention as a qualifying statement that single-agent chemotherapy is preferred over multi-agent chemotherapy. And the second recommendation was that, in patients with relapsed small cell lung cancer with a chemotherapy interval longer than 90 days, the rechallenge with a platinum-based regimen or single-agent chemotherapy was considered standard and the preferred agents for single agent therapy would be topotecan, lurbinectedin, or tarlatamab being added in the recent study. Tarlatamab was approved by the FDA for use in patients with relapsed small cell lung cancer with no stipulations with regard to the treatment. Brittany Harvey: Understood. I appreciate you describing those updated recommendations along with the supporting data for both limited stage small cell lung cancer and relapsed small cell lung cancer. So then, what should clinicians know as they implement these new and updated recommendations into practice? Dr. Greg Kalemkerian: So with regard to the ADRIATIC trial or the consolidation durvalumab being added for limite- stage small cell lung cancer patients, I think the important considerations are that this was done after patients had demonstrated no progression of disease after chemotherapy and radiotherapy, so the initial treatment does not change with platinum-etoposide plus definitive radiotherapy being recommended. The addition of durvalumab is going to be potentially useful in patients generally with good performance status, so performance statuses 0 to 1, and we still have to pay attention to the patients who may have contraindications to immunotherapy, things like interstitial lung disease, autoimmune problems that do occur in patients with small cell lung cancer where they develop paraneoplastic autoimmune syndromes such as Lambert-Eaton myasthenic syndrome. Those patients with those types of preexisting conditions would not be good candidates for immunotherapy use. So still having the tailored treatment to the individual patient is what's most important. The duration of the durvalumab was up to two years and not beyond that, so following those specific guidelines for the use of durvalumab in patients with limited-stage small cell lung cancer. With regard to tarlatamab, tarlatamab is an immunotherapy treatment. So we still do have the exclusions of people who have had prior severe immune-related adverse events, people who have pneumonitis, people who have interstitial lung disease, people with autoimmune neurologic problems we can see with small cell lung cancer, these patients should not be considered good candidates for the use of tarlatamab. The study did include patients who had had treated and asymptomatic brain metastases and there is some evidence that tarlatamab can have some control of brain metastases. So that's not necessarily an exclusion. Tarlatamab does have some other specific considerations to it in that 51% of patients had some evidence of cytokine release syndrome (CRS). Only 1% of those patients had grade 3 CRS. So even though they had frequent fevers and hypotension and hypoxia, it was generally not severe. But this concern for CRS and also for neurologic complications after treatment does require that patients be admitted to the hospital for a 24-hour observation period during the first and second doses. Subsequent to that, patients can be observed for some time after the infusion in the outpatient setting. But they also need to have very clear and strict guidance for when they go home about what things to look for. Looking for fevers, looking for shortness of breath, looking for any neurologic changes. It's a good idea for them to have a caregiver with them in order to observe them during that time. Most of these complications occur during the first or second cycles, but it is a drug that is going to require significant education not only of our staff, but also of the patients in order to ensure that the drug's used safely. Brittany Harvey: Absolutely. For these new options, it's important to tailor cancer treatment to the individual patient and the factors that you mentioned and be mindful of these potential toxicities. So, it's always great to learn of new options for patients. But in your view, how will this update impact patients with small cell lung cancer? Dr. Greg Kalemkerian: Well, clearly we need longer term follow up. So, with regard to the limited-stage small cell lung cancer situation, that's a curative situation. We have been curing patients with limited-stage disease with chemotherapy and radiotherapy for several decades now, but the cure rates were relatively low with about 25%, 30% of people becoming long term survivors. Now the hope is with the durvalumab being added on, that we can increase that number. Thus far, we have three-year survival data with a three-year survival of 57% overall survival and we're hoping that that is maintained over time and that we're not just delaying recurrences, but that we're actually preventing recurrences and helping people live longer, as has been seen with non-small cell lung cancer in stage III disease with the addition of durvalumab to chemoradiotherapy. So hopefully, we will be improving the cure rate of people with limited-stage small cell lung cancer. There are several other trials with immunotherapy in this space coming down the line and we're anxiously awaiting not only long term follow up from ADRIATIC, but also initial data from studies such as KEYLYNK and ACHILLES and NRG-LU005. So all of these studies in the next few years are hopefully going to guide treatment for limited-stage small cell lung cancer and hopefully improve the long term survival outcomes. With regard to tarlatamab, unclear at this point what the long term outcomes are going to be. Is a 40% response rate substantially better than what we've seen before? Well, lurbinectedin also had about a 40% response rate in patients who had sensitive disease, but the duration of response does look longer. And there are some patients now who have been on this study that are doing very well for quite long periods of time with the drug. So, the hope here also is that we will have some small subset of patients who continue to do better for long periods of time. Whether that'll translate into a cure or not, way too early to know, clearly hoping to add another brick in the wall so that we can keep the disease at bay, at least for a longer period of time for these patients. How we will integrate tarlatamab into the regimens is a bit unclear. Whether most of us will start using it as second-line therapy or whether we will use perhaps lurbinectedin or topotecan as second-line and tarlatamab as third-line, we're all going to have to work that out based on the potential toxicities, the logistical complications of using the drug at this point in time. But I do think that it's nice to have more options to add to our armamentarium to treat this very, very challenging and difficult disease. Brittany Harvey: Definitely. So, you've just discussed the need for both longer term follow up here along with some important ongoing trials in this space. So we'll look forward to future readouts of those trials to learn more about caring for patients in small cell lung cancer. So, I want to thank you so much for your work to rapidly update this guideline and thank you for your time today, Dr. Kalemkerian. Dr. Greg Kalemkerian: Okay. Again, thank you for the invitation, Brittany, and thanks to ASCO for developing the whole guideline structure to help all of us take better care of our patients. Brittany Harvey: Absolutely. And also thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full update, go to www.asco.org/thoracic-cancer-guidelines.  You can also find many of our guidelines and interactive resources in the free ASCO Guidelines App available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.

Housepedia Podcasts #HomeIsWhereHouseIsPlaying 169 I Paola Piancastelli Paola Piancastelli is an Italian DJ based in Riccione, on the Adriatic coast. She is a resident DJ and music selector for Unify Radio, hosting a weekly Sunday evening show called *Motion*. Paola has been passionate about Jazz, Funk, Disco, and House Music since childhood. Info about the artist: @paola-piancastelli Submit your mixtape: https://linktr.ee/housepediamusic Listen on Apple: apple.co/3n4V8s5v

Lung cancer treatment has changed seismically since 2018 and the NEJM publication of Keynote 189. This week, we have Dr. Ned Mcnamee on the show to give us his highlights of lung cancer updates from ESMO 2024. He explores the resectable lung cancer space with Checkmate-77T; crosses the ADRIATIC trial in patients with limited-stage small cell lung cancer, and brings in a home run with an updated LAURA trial mention (osimertinib after definitive chemoradiotherapy)Links to studies discussed in this episode (subscription may be required):Checkmate77TADRIATICLAURASpecial mentionsFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comOncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Trevor is joined by Aurora and Roberto from Tsar Power (@TsarPowerPod) to form an unholy alliance of altogether too many podcasts and discuss how the United States occupied a slice of the Croatian coast after World War 1 and helped the newly formed Yugoslavia fend off Italian nationalists. Also, the Italians invent fascism along the way.Visit https://hopfulmedia.com.co to subscribe, donate, or buy podcast merch!The History of Saqartvelo Georgia https://podcasters.spotify.com/pod/show/historysaqartvelogeorgiaTsar Power https://tsarpowerpod.weebly.com/Quest for Power https://quest-for-power.captivate.fm/Swords, Sorcery, and Socialism https://swordsandsocialismpod.buzzsprout.com/Davidonis 1943 - American Naval Mission in the Adriatic, 1918-1921Davidonis 1945 - American Naval Mission In The Adriatic, 1918-1921Field - Split, 1919Hughes-Hallett - Gabriele d'Annunzio: Poet, Seducer, and Preacher of WarImperial Valley Press 27 - Knox Queries About MarinesJakir - Reactions in Dalmatia to the Treaty of Rapallo 1920James - Says Serb Troops Recaptured TrogirMorning Press 48.23 - U.S. Navy Ousts Italians From Dalmation CityNHHC - NH 111504Nye - Dalmatia, Centre of War's Shifting SpotlightNYT - U.S. Marines Saved Italians At TrogirNYT - Trogir Recovered Without A Fight By Olympia's MenSan Luis Obispo Daily Telegram 178 - Senate Wants Facts As To LandingSimonelli - The lions' retaliation: D'Annunzio and the italian nationalist mythology in Dalmatia

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Stephen Liu, Associate Professor and Director of Thoracic Oncology at the Georgetown Lombardi Comprehensive Cancer Center. Together, they dive into the latest findings from ESMO 2024, focusing on key studies in lung cancer that every community oncologist should be aware of. Episode Highlights: •⁠  ⁠LAURA Trial: Discussing the role of osimertinib in locally advanced unresectable EGFR-mutant lung cancer post-chemoradiation and its impact on CNS progression-free survival. •⁠  ⁠MARIPOSA and MARIPOSA-2 Studies: Exploring the importance of amivantamab in metastatic non-small cell lung cancer, including insights on resistance patterns and treatment sequencing. •⁠  ⁠ADRIATIC Study: Analyzing the use of durvalumab as consolidation therapy in limited-stage small cell lung cancer and its implications for practice, including updates on prophylactic cranial irradiation (PCI). Join us as we unpack these pivotal studies that are shaping the future of lung cancer treatment. Don't forget to check out our highlights on GI, GU, and breast cancer from ESMO 2024! Subscribe for more insights and updates in oncology! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com    

Morse code transcription: vvv vvv Gary Lineker says BBC contract talks over Match of the Day have just started Mexican mayor murdered days after starting job Nobel Prize goes to microRNA researchers Chris Mason Why it was always likely Sue Gray would go Food rating lies exposed by BBC secret recording Madonna pays tribute to brother Christopher Ciccone House prices close to record high, says Halifax Oasis on the Adriatic where Ukrainians and Russians have gone to escape war Cardiff Half Marathon Runner dies after 2024 race How perfect storm blew away planned social homes England needs

Morse code transcription: vvv vvv Gary Lineker says BBC contract talks over Match of the Day have just started Mexican mayor murdered days after starting job House prices close to record high, says Halifax Nobel Prize goes to microRNA researchers Madonna pays tribute to brother Christopher Ciccone Oasis on the Adriatic where Ukrainians and Russians have gone to escape war How perfect storm blew away planned social homes England needs Cardiff Half Marathon Runner dies after 2024 race Food rating lies exposed by BBC secret recording Chris Mason Why it was always likely Sue Gray would go

Morse code transcription: vvv vvv Food rating lies exposed by BBC secret recording Oasis on the Adriatic where Ukrainians and Russians have gone to escape war How perfect storm blew away planned social homes England needs Mexican mayor murdered days after starting job Cardiff Half Marathon Runner dies after 2024 race House prices close to record high, says Halifax Chris Mason Why it was always likely Sue Gray would go Madonna pays tribute to brother Christopher Ciccone Nobel Prize goes to microRNA researchers Gary Lineker says BBC contract talks over Match of the Day have just started

Morse code transcription: vvv vvv Madonna pays tribute to brother Christopher Ciccone How perfect storm blew away planned social homes England needs Cardiff Half Marathon Runner dies after 2024 race Gary Lineker says BBC contract talks over Match of the Day have just started Food rating lies exposed by BBC secret recording Mexican mayor murdered days after starting job House prices close to record high, says Halifax Chris Mason Why it was always likely Sue Gray would go Oasis on the Adriatic where Ukrainians and Russians have gone to escape war Nobel Prize goes to microRNA researchers

Ep 83 Part 1 Come along with Donna and Dr Adam and experience the famous ancient village of Alberobello in Southern Italy with its well-preserved Trulli houses in this special video episode! From Donna: "In 1967, I found myself in a Warner Bros recording studio in Rome, Italy. I was asked to sing a theme to a movie called "Once Before I Die", starring Ursula Andress. To promote the song Warner Bros. sent me down the coast of the Adriatic to a tiny mountain town called Alberobello. This was an ancient village, well preserved with the unique Trulli style houses made of lime and slate. A video was made of me standing on old Roman ruins singing the song. My collaborator and producer, Dr. Adam Gerace, recently traveled to Italy and visited Alberobello which has given me an opportunity to share this very rare unreleased recording along with photos taken by my dad, Morey, during our 1960's stay. Never dreamed this would become a reality and I sincerely hope you enjoy it!" Note: Ep 83 Part 2 (Audio) - A Travel Diary from Alberobello to Milan This companion Audio Podcast is available on YouTube, Apple, Spotify, Amazon, iHeart or wherever you get your podcasts.

In this episode we download Donna's recent trip to Italy for more fun and adventury internationally.  Accomodations were in historic structures and we talk about horizon lines, perspective and plumbing as we bring this back to our industry of real estate.  Toss in some references to Up With People, traveling with youthful near centairans, gourmet meals and dining, and painting there was painting. Join as we talk Boutique experiential travel on the Adriatic side of Northern Italy as we do what we do and blend this in with real estate and lifestyle. Your hosts are Donna Reed and Eric Seemann. Both are professional real estate agents. Donna lives and works in Tucson Arizona with Keller Williams Southern Arizona while Eric lives and works in San Antonio Texas with Keller Williams Heritage. They are also siblings, and they grew up in a small Northwest Ohio village of Lindsey. Their idyllic small-town childhood laid the foundation for what would become the structure of their lives and careers in real estate. We hope you will join us as we reminisce, reflect, and correlate how our childhood and life in rural Ohio still impacts our dealings with our clients today. Website:  www.realsiblings.com Watch Episodes on YouTube at:  REAL Siblings, It Ain't Easy   To reach out to Donna: Email:  donna@reedtucson.com Phone: (520) 631-4638 Facebook: (2) Donna Seemann Reed | Facebook   To Connect with Eric: Email:  eric@victorsgrouptx.com Phone: (210) 389-6324 Facebook: (2) Eric V. Seemann | Facebook   Texas Real Estate Commission - Information About Brokerage Services Texas Real Estate Commission - Consumer Protection Notice    

Full Text of ReadingsMemorial of Saint Pius of Pietrelcina, Priest Lectionary: 449The Saint of the day is Saint Pio of PietrelcinaSaint Pio of Pietrelcina's Story In one of the largest such ceremonies in history, Pope John Paul II canonized Padre Pio of Pietrelcina on June 16, 2002. It was the 45th canonization ceremony in Pope John Paul's pontificate. More than 300,000 people braved blistering heat as they filled St. Peter's Square and nearby streets. They heard the Holy Father praise the new saint for his prayer and charity. “This is the most concrete synthesis of Padre Pio's teaching,” said the pope. He also stressed Padre Pio's witness to the power of suffering. If accepted with love, the Holy Father stressed, such suffering can lead to “a privileged path of sanctity.” Many people have turned to the Italian Capuchin Franciscan to intercede with God on their behalf; among them was the future Pope John Paul II. In 1962, when he was still an archbishop in Poland, he wrote to Padre Pio and asked him to pray for a Polish woman with throat cancer. Within two weeks, she had been cured of her life-threatening disease. Born Francesco Forgione, Padre Pio grew up in a family of farmers in southern Italy. Twice his father worked in Jamaica, New York, to provide the family income. At the age of 15, Francesco joined the Capuchins and took the name of Pio. He was ordained in 1910 and was drafted during World War I. After he was discovered to have tuberculosis, he was discharged. In 1917, he was assigned to the friary in San Giovanni Rotondo, 75 miles from the city of Bari on the Adriatic. On September 20, 1918, as he was making his thanksgiving after Mass, Padre Pio had a vision of Jesus. When the vision ended, he had the stigmata in his hands, feet, and side. Life became more complicated after that. Medical doctors, Church authorities, and curiosity seekers came to see Padre Pio. In 1924, and again in 1931, the authenticity of the stigmata was questioned; Padre Pio was not permitted to celebrate Mass publicly or to hear confessions. He did not complain of these decisions, which were soon reversed. However, he wrote no letters after 1924. His only other writing, a pamphlet on the agony of Jesus, was done before 1924. Padre Pio rarely left the friary after he received the stigmata, but busloads of people soon began coming to see him. Each morning after a 5 a.m. Mass in a crowded church, he heard confessions until noon. He took a mid-morning break to bless the sick and all who came to see him. Every afternoon he also heard confessions. In time his confessional ministry would take 10 hours a day; penitents had to take a number so that the situation could be handled. Many of them have said that Padre Pio knew details of their lives that they had never mentioned. Padre Pio saw Jesus in all the sick and suffering. At his urging, a fine hospital was built on nearby Mount Gargano. The idea arose in 1940; a committee began to collect money. Ground was broken in 1946. Building the hospital was a technical wonder because of the difficulty of getting water there and of hauling up the building supplies. This “House for the Alleviation of Suffering” has 350 beds. A number of people have reported cures they believe were received through the intercession of Padre Pio. Those who assisted at his Masses came away edified; several curiosity seekers were deeply moved. Like Saint Francis, Padre Pio sometimes had his habit torn or cut by souvenir hunters. One of Padre Pio's sufferings was that unscrupulous people several times circulated prophecies that they claimed originated from him. He never made prophecies about world events and never gave an opinion on matters that he felt belonged to Church authorities to decide. He died on September 23, 1968, and was beatified in 1999. Reflection Referring to that day’s Gospel (Matthew 11:25-30) at Padre Pio's canonization Mass in 2002, Saint John Paul II said: “The Gospel image of ‘yoke' evokes the many trials that the humble Capuchin of San Giovanni Rotondo endured. Today we contemplate in him how sweet is the ‘yoke' of Christ and indeed how light the burdens are whenever someone carries these with faithful love. The life and mission of Padre Pio testify that difficulties and sorrows, if accepted with love, transform themselves into a privileged journey of holiness, which opens the person toward a greater good, known only to the Lord.” Learn more about Padre Pio! Saint of the Day, Copyright Franciscan Media

Recapping just some of the notable data coming out of ESMO 2024: -Final OS results from Keynote-522 (perioperative pembrolizumab in TNBC) -AMBASSADOR (adjuvant pembrolizumab in bladder cancer) -NIAGRA (perioperative durvalumab in bladder cancer) -ADRIATIC (discussed on ASCO recap Pod, but publication now available) -LEANOX (impact of lean body mass adjustment on oxaliplatin dose)

The first Venice episode was # 247. I came back and added more to that here and the following episode.  In this episode, the FAQ is: Would I return to Venice? Today's Destination is Venice, Italy Part 2 of 3 Today's Misstep: Spend more time in the region of Northern Italy.   Travel Advice: In Venice, Get Lost FAQ: Would I go back to Venice?   Answer: The answer is yes because I hardly saw the main attractions the first time. I was in a crowd of tourists, and it was under construction. I think there will be better crowd control now that there's a fee. Today's destination: Venice, Italy Part 2 of 3 Venice is called the City of Dreams.  It's the capital of northern Italy's Veneto region and is built on over 100 small islands in a lagoon in the Adriatic Sea. It has no roads, just canals—including the Grand Canal thoroughfare—lined with Renaissance and Gothic palaces. The central square, Piazza San Marco, contains St. Mark's Basilica, tiled with Byzantine mosaics, and the Campanile bell tower, which offers views of the city's red roofs.  Yes, Venice is sinking. This is due to sediment settling and freshwater pumping from below ground. What are the main places to explore here?   Take the canals everywhere, because there are no cars.   So many corners. Away from glitter and gloss. 70,000 people live here. Tens of millions vacation here. https://whc.unesco.org/en/list/394/   Detours throughout the city due to construction. Rialto Bridge is in the middle of the busy tourist activity.   If I had more time, I would have spent it in Venice. I only had four days, which got me more interested in being part of the city life. I'd go back outside of the summertime. I'd visit the historical sites and ride the vaporettas, trains, and buses. I'd also explore the area around Venice to learn about its history and meet the people. Today's Travel Advice- In Venice, Get Lost    

Spring, summer and fall of 1081 — There is so much happening on both sides of the Adriatic during this time period. On this episode, we will keep up to date on it all. You won't want to miss it! Members-Only Series on Patreon: For only a dollar per month, you can hear multiple varying stories and storylines so far through the 11th century, including but not limited to the creation of the Kingdom of Poland, what's happening on the Continent while Duke William is conquering England, and, currently, our series called “The Book of Alexios” detailing all those details of the monumental medieval emperor, Alexios Komnenos, that didn't make it into the public podcast. Every dime donated will be put directly back into the show, so I hope you consider becoming a Patreon member!  Just follow this link to our Patreon page to peruse the right “subscription” for you: https://www.patreon.com/FortunesWheelPodcast.  Social Media: YouTube Page: Fortune's Wheel Podcast Facebook Page: https://www.facebook.com/fortunes.wheel.3  Twitter Page: https://twitter.com/WheelPodcast

Welcome to another fascinating episode recap from the "Hustle and Flowchart" podcast! This time, I had the pleasure of speaking with Ronan McMahon, a globetrotting international real estate investor, about his intriguing lifestyle and the wisdom he's gleaned from his global property investments. Ronan sheds light on his global lifestyle, revealing how he organizes his year around 3 different bases: Cabo San Lucas in Mexico for winter, Portugal for spring and fall, Ireland for summer. His journey from the corporate world to international real estate investment offers insightful perspectives on embracing travel and profiting from emerging global markets. Introduction to Ronan McMahon Ronan McMahon is an international real estate investor who travels the world to find promising property markets. He started his journey not with a grand plan, but out of disillusionment with his corporate job. Successful property investments gave him the freedom to explore international real estate, leading him to establish multiple bases around the world. Choosing Key Bases Ronan organizes his year around living in key locations, each chosen for specific reasons: Cabo San Lucas in Mexico during winter for its warm climate, Portugal in spring and fall for its pleasant weather, Ireland in summer to enjoy family and friends, and another base in Mexico for intense business activities and convenient travel. He emphasizes that this setup not only suits his lifestyle but also enhances his productivity and mental clarity. Joe Fier related Ronan's use of bases to the business strategy of time blocking, noting how both can streamline operations and reduce inefficiencies. The Importance of Climate and Lifestyle Climate plays a crucial role in Ronan's choices. He explains that the climate of each location allows him to think clearly and stay energized. Moreover, balancing work and lifestyle helps him stay connected to family and friends. Ronan values “slow travel” experiences, such as taking leisurely ferries, which lets him observe and appreciate new places more deeply. Avoiding peak tourist times also helps him manage crowds and costs effectively. Transition from Corporate Disillusionment to Investment Success Ronan's international lifestyle emerged from his disillusionment with the corporate world. Successful property investments allowed him to quit his job and pursue a path he was passionate about. Rather than extensive planning, his journey evolved organically from opportunities that presented themselves, emphasizing the importance of staying open to change and being adaptable. Global Trends and Market Opportunities McMahon discusses the rising bureaucracy, high costs, and scarcity in developed countries. These factors drive people to seek alternatives, like international real estate investments. He identifies three key locations currently ripe for investment: Montenegro, Panama City, Panama, and Guanacaste in Northern Costa Rica. For example, Montenegro on the Adriatic coastline is attracting high-end investors due to its beautiful landscapes and strategic location. Panama offers a safe and thriving environment for multinational corporations, providing high rental yields with minimal holding costs. Ronan's Real Estate Trend Alert members receive exclusive deals in these promising locations, such as special pricing and terms on residential properties. A notable benefit is being the first to grasp emerging trends and potential investments. Ronan McMahon's Website Tips for Aspiring Real Estate Investors Ronan offers practical advice for those new to real estate investing. He recommends embracing travel and experiencing potential investment locations firsthand. Renting an Airbnb for a month can provide insights into the local lifestyle and investment opportunities. Ronan calls this the "boots on the ground" approach, where physically visiting and testing locations help one understand the true value and experience of the place. Joe Fier also weighs in, mentioning Ronan's book on profitable real estate investing. The book is positioned as a comprehensive guide for beginners, and Joe plans to read it for its valuable insights. Ronan emphasizes the importance of investing in real estate ahead of emerging trends for maximum growth and returns. Key Takeaways and Ronan's Advice Ronan McMahon's experiences and strategies offer valuable lessons for both seasoned and new real estate investors. His emphasis on choosing locations based on climate, lifestyle, and market potential underscores the importance of a balanced and informed approach to investments. By physically visiting and experiencing these locations, one can make better informed decisions. Whether you're looking to diversify your portfolio or considering a lifestyle change, Ronan's insights provide an encouraging roadmap. In summary, this episode stresses the significance of adaptability, informed decision-making, and embracing new opportunities. Tune in to this and future episodes for more tips and strategies to enhance your hustle and streamline your flowchart! Stay tuned for more discussions about innovative ways to navigate the world of real estate and beyond.  Two Other Episodes You Should Check Out Unlocking Passive Income Through Real Estate with Tom Burns Joe Sanok – The #1 Secret for Creating the Lifestyle you Always Wanted Resources From Episode Accelerate growth with HubSpot's Sales Hub Check out other podcasts on the HubSpot Podcast Network Grab a 30-Day Trial of Kartra We want to hear from you. Send us the One Thing you want to hear on the show. Connect with Joe on LinkedIn and Instagram Subscribe to the YouTube Channel Contact Joe: joe@hustleandflowchart.com Thanks for tuning into this episode of the Hustle & Flowchart Podcast! If the information in these conversations and interviews have helped you in your business journey, please head over to iTunes (or wherever you listen), subscribe to the show, and leave me an honest review. Your reviews and feedback will not only help me continue to deliver great, helpful content, but it will also help me reach even more amazing entrepreneurs just like you!

Leeds must go above and beyond to ensure the summer of 2024 is not remembered for countless exits and too few replacements. Graham and Joe reconvene after the former's jolly jaunt on the Adriatic coast to discuss what's going on at Elland Road with incoming transfers and the season so far. Listen, share and subscribe now.

This episode of Mining Stock Daily is brought to you by...  Arizona Sonoran Copper Company (ASCU:TSX) is focused on developing its brownfield copper project on private land in Arizona. The Cactus Mine Project is located less than an hour's drive from the Phoenix International airport. Grid power and the Union Pacific Rail line situated at the base of the Cactus Project main road. With permitted water access, a streamlined permitting framework and infrastructure already in place, ASCU's Cactus Mine Project is a lower risk copper development project in the infrastructure-rich heartland of Arizona.For more information, please visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.arizonasonoran.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Fireweed Metals is advancing 3 different projects within the Yukon and Northwest Territories, including the flagship Macmillan Pass Project, a large zinc-lead-silver deposit and the Mactung Project, one of the largest and highest-grade tungsten deposits in the world. Fireweed plans to advance these projects through exploration, resource definition, metallurgy, engineering, economic studies and collaboration with indigenous people on the path to production. For more information please visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠fireweedmetals.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

The Italian town of Monfalcone on the Adriatic coast has an ethnic make-up unique to the country. Of a population of just over thirty thousand, more than six thousand are from Bangladesh. They've come to help construct huge cruise ships, providing labour to do the type of manual jobs which Italians no longer want to do.For years, they worshipped at two Islamic centres in the town. Then, in November, the town's far right mayor, Anna Maria Cisint, tried to effectively ban collective prayer there, along with stopping cricket - the Bangladeshi national sport - from being played within the town.She says she is defending Christian values. Her critics say she is building walls rather than bridges. For Assignment, Sofia Bettiza travels to Italy to discover how the country is dealing with the increasing numbers of legal migrants coming to work in a country which needs their labour.

The Italian town of Monfalcone on the Adriatic coast has an ethnic make-up unique to the country. Of a population of just over thirty thousand, more than six thousand are from Bangladesh. They've come to help construct huge cruise ships, providing the cheap labour to do the type of manual jobs which Italians no longer want to do. For years, they worshipped at two Islamic centres in the town. Then, in November, the town's far right mayor, Anna Maria Cisint, tried to effectively ban collective prayer there, along with stopping cricket - the Bangladeshi national sport - from being played within the town. She says she is defending Christian values. Her critics say she is building walls rather than bridges. For Crossing Continents, Sofia Bettiza travels to Italy to discover how the country is dealing with the increasing numbers of legal migrants coming to work in a country which needs their labour.Producer: Bob Howard Presenter: Sofia Bettiza Studio Manager: Rod Farquhar Production Coordinator: Gemma Ashman Editor: Penny Murphy

Drs. Balazs Halmos and Lecia Sequist delve into the groundbreaking updates from the 2024 ASCO Annual Meeting. With Chadi, they reveal game-changing insights on EGFR-mutated lung cancer from the LAURA trial, small-cell lung cancer upgrades from the ADRIATIC trial, important revelations in ALK mutation research, innovative combination therapies, ctDNA results from the ADAURA trial, and conclude with the relevance of the KRYSTAL-12 study. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Join the Oncology Brothers, Rahul and Rohit Gosain, in this insightful podcast episode as they dive into the world of small cell lung cancer with special guest Dr. Eric Singhi, a thoracic medical oncologist from MD Anderson Cancer Center. Key Points: •⁠  ⁠The Adriatic study's impact on improving survival with Durvalumab in limited-stage disease. •⁠  ⁠Treatment options for extensive-stage disease, including second-line therapies like Lurbinectedin and the recent approval of Tarlatamab. •⁠  ⁠The significance of individualized treatment decisions and ongoing research in small cell lung cancer management. In this episode, Dr. Singhi discusses the management of limited-stage small cell lung cancer, the impact of the recent Adriatic study on treatment approaches, and the use of immunotherapy in both limited and extensive-stage disease. The conversation also delves into the role of PCI, the use of Trilaciclib in extensive stage, and the recent FDA approval of Tarlatamab for small cell lung cancer. Discover the latest advancements and treatment options for small cell lung cancer, including insights on second-line treatments, consolidation radiation, and the management of patients with driver mutations. Dr. Singhi also highlights the importance of patient advocacy groups like the Small Cell Smashers in providing support for individuals with small cell lung cancer. Tune in to this episode for a comprehensive overview of the current treatment landscape for small cell lung cancer and gain valuable insights from Dr. Singhi's expertise in the field. Don't miss out on this informative discussion on the Oncology Brothers podcast!

OncLive On Air partners with Two Onc Docs to bring insights on the ADRIATIC trial, data from which were presented at the 2024 ASCO Annual Meeting.

This week's episode will discuss updates from ASCO 2024 next with the practice changing ADRIATIC trial presented by Dr. Spigel during the plenary: Durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer (LS-SCLC). 

Welcome to the new moon in cancer meditation. For this water sign at the beginning of the summer season we will be traveling to a rustic old stone villa on the Adriatic in croatia. This new moon is about setting intentions for your true emotions, what authentic desires does your soul have. Using the salt water and the coastline to embody those intentions.@topanga_moon

Drs. John Sweetenham and Angela DeMichele discuss potentially ground-breaking abstracts in breast and lung cancer as well as notable research on artificial intelligence and its impact on cancer care, all of which were featured at the 2024 ASCO Annual Meeting.  TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center and host of the ASCO Daily News Podcast. My guest today is Dr. Angela DeMichele, the Marianne and Robert McDonald Professor in Breast Cancer Research and co-leader of the Breast Cancer Program at the University of Pennsylvania's Abramson Cancer Center. Dr. DeMichele also served as the chair of the 2024 ASCO Annual Meeting Scientific Program. Today, she'll be sharing her reflections on the Annual Meeting and we'll be highlighting some advances and innovations that are addressing unmet needs and accelerating progress in oncology.  Our full disclosures are available in the transcript of this episode.  Dr. DeMichele, congratulations on a very robust and highly successful program at ASCO24, and thanks for joining us on the podcast today. Dr. Angela DeMichele: Well, thanks so much for having me, Dr. Sweetenham. It's a pleasure to be here.  Dr. John Sweetenham: The presidential theme of the Annual Meeting this year was the "The Art and Science of Cancer Care: From Comfort to Cure." And this was certainly reflected throughout the meeting in Chicago that welcomed more than 40,000 attendees from across the globe. I know our listeners will be interested to hear some of your own reflections from the meeting now that we're on the other side of it, so to spea  Dr. Angela DeMichele: Yes. Well, I will say that playing this role in the annual meeting really was a highlight of my career, and I feel so fortunate to have had the opportunity to do it. We had over 200 sessions, and in many, if not all of these sessions, we really tried to make sure that there was a case that really sort of grounded the session to really help people understand: you're going to hear about science, but how are you going to apply that? Who is the patient for whom this science really is important?  We had over 7,000 abstracts submitted, and our 25 tracks and their chairs really pulled through to find really the best science that we could present this year. I think what you saw really was a representation of that across the board: incredible advances in lung cancer, breast cancer, melanoma, GI cancers; also really cutting-edge technologies: AI, as we'll talk about in a little while circulating markers like ctDNA, new drug development, new classes of drugs. So it was really an exciting meeting. I mean, some highlights for me, I would say, were certainly the Plenary, and we can talk a little bit about that. Also, we had a fantastic ASCO/AACR Joint Session on “Drugging the “Undruggable Target: Successes, Challenges, and the Road Ahead.” And, if any of the listeners have not had a chance to hear this, it's really worth going in and watching this because it really brought together three amazing speakers who talked about the successes in KRAS, and then really, how are we using that success in learning how to target KRAS to now targeting a variety of other previously thought to be undruggable targets. I learned so much. And there's really both the academic and the pharma perspective there. So I'd really encourage watching this session. The other session that I really thought was terrific was one that I was honored to chair, which was a fireside chat (“How and Where Will Public Investment Accelerate Progress in Oncology? A Discussion with the NIH and NCI Directors”) with both Dr. Monica Bertagnolli, who is the director of the NIH, and Dr. Kim Rathmell, who's now the director of the NCI. And boy, I'll tell you, these two incredibly smart, thoughtful, insightful women; it was a great conversation. They were really understanding of the challenges we face conducting research, practicing medicine. And maybe different from leadership at the NIH in the past, they've really taken the approach to say that everything they do is focused on the patient, and they don't limit themselves to just research or just science, that everything that the NIH does, and particularly the NCI does, really has to be focused on making sure we can give patients the best possible care. And I think they're being very thoughtful about building important infrastructure that's going to take us into the future, incorporating AI, incorporating new clinical trial approaches that are going to make it faster and easier to conduct clinical trials and to get the results that we need sooner. So just a few of the highlights, I think, from some really interesting sessions. Dr. John Sweetenham: It certainly was an extremely enriching and impactful ASCO24. And I think that the overall theme of the meeting was extremely well reflected in the content with this amazing mix of really, truly impactful science, along with a great deal of patient-centered healthcare delivery science to accompany it. So, I completely agree with you about that. There was a lot, of course, to take in over the five days of the meeting, but I'm sure that our listeners would be very interested to hear about one or two abstracts that really stood out for you this year.  Dr. Angela DeMichele: Sure. I'm a breast cancer specialist, so I can't help but feel that the late breaking abstract, the DESTINY-Breast06 trial, was really important for the field of breast cancer. So just briefly, this is a study of the antibody drug conjugate T-DxD, trastuzumab deruxtecan. This is a drug that is actually now approved in metastatic breast cancer, really effective in HER2-positive disease. But the question that this trial was trying to answer is, can this drug, which is built with the herceptin antibody against HER2, then linked to a chemotherapeutic molecule, can this work even in the setting of very, very low HER2 expression on a tumor? I think this is an incredibly important question in the field of antibody drug conjugates, of which there are now many across diseases, is how much of the target do you really need to have on the surface of the tumor?  We had seen previously HER2 overexpressing tumors respond really well to this drug. HER2 tumors that have an intermediate level of expression were tested in the DP04 trial, and we saw that even those 2+ intermediate tumors responded well to this drug. The DP06 trial that was presented at ASCO was looking at this group of patients that have even less HER2 on the surface. So we typically measure HER2 by immunohistochemistry as 0, 1+, 2+, or 3+. And this was looking at patients whose tumors were over 0, but were at 1+ or below, so low and ultra-low. And it turned out that compared to treatment of physician's choice, the drug really had quite a lot of activity, even in these patients who have very little HER2 on their tumors, really showing progression-free survival benefits in the HER2-low and HER2-ultra-low groups that were appreciable on the order of about 5 months, additional progression free survival hazard ratios around 0.6, so really demonstrating that utilizing an antibody drug conjugate, where you've got very little target, can still be a way to get that drug to a tumor.   And I think it'll remain to be seen whether other ADCs can have activity at very low levels of IHC expression of whatever target they're designed against. I think one of the tricky things here for implementing this in breast cancer will be how do pathologists actually identify the tumors that are ultra-low because it's not something that we typically do. And so we'll go through a period, I think, of adjustment here of really trying to understand how to measure this. And there are a bunch of new technologies that I think will do a better job of detecting low levels of the protein on the surface of the tumor because the current IHC test really isn't designed to do that. It was only designed to be focused on finding the tumors that had high levels. So we have some newer technologies with immunofluorescence, for example, that can really get down to very low levels. And I think this is going to be a whole new area of ADCs, target detection – how low can you go to still see activity? So I thought that this was an important abstract for many reasons.  I will just say the second area that I was really particularly impressed with and had a big impact on me were the two lung cancer abstracts that were presented in the Plenary, the LAURA trial (LBA4) and the ADRIATIC trial (LBA5). And I think, I've been in the field of oncology for 30 years now, and when I started in the late ‘90s, lung cancer was a disease for which we had very few treatments. If we didn't catch it early and surgery wasn't possible for non-small cell lung cancer, really, it was a horrible prognosis. So we knew this year was the 20th anniversary of the discovery of EGFR as a subtype of lung cancer. That was really, I think, a turning point in the field of non-small cell lung cancer – finding a target. And now seeing the LAURA trial show that osimertinib really had such an enormous impact on progression-free survival amongst these patients who had EGFR-positive non-small cell lung cancer, progression-free survival hazard ratio of 0.16; there was a standing ovation.  And one of the really big privileges of being the Scientific Program Chair is getting to moderate the Plenary Session, and it's a really amazing experience to be standing up there or sitting there while the presenter is getting a standing ovation. But this was well deserved because of the impact this is having on patients with EGFR positive lung cancer. And it was similar with the ADRIATIC trial, which looked at the benefits of adding immunotherapy in limited-stage small-cell lung cancer. Again, a disease that treatment has not changed in 30 years, and so the addition of durvalumab to the standard backbone of chemotherapy for small cell lung cancer had its survival advantage. These patients are living longer and it was really an impressive improvement. And I think it really underscores just the revolution that has happened in lung cancer between targeted therapy and immunotherapy has completely changed the prognosis for patients with this disease. So to me, these were really landmark reports that came out at ASCO that really showed us how far we've come in oncology. Dr. John Sweetenham: Yeah, absolutely. I think that, as you mentioned, those results are truly remarkable, and they reflect extraordinary advances in science. I think we see that both in terms of the therapeutic arena, but also, I think we've started to see it in other areas as well, like symptom control, remote patient monitoring, and so on and so forth, where some of the newer virtual technologies are really having major impacts as well. Dr. Angela DeMichele: Yes, we really wanted to have a focus on artificial intelligence in this meeting, because it's having such an enormous impact on our field in everything from care delivery to diagnostics. I'd love to hear what you thought was the most interesting, because there really was just new data across the board presented. Dr. John Sweetenham: I've actually chosen 3 abstracts which I thought were particularly interesting for a couple of reasons, really. They're all based on virtual health interventions, and I think they're interesting in really reflecting the theme of the meeting, in that they are extremely advanced technology involved in the virtual platforms, a couple of which are artificial intelligence, but very impactful to patients at the same time in terms of remote symptom control, in terms of addressing disparities, and in one case, even influencing survival. So I thought these were three really interesting abstracts that I'll walk the listeners through very quickly.  The first of these was a study, Abstract 1500 (“National implementation of an AI-based virtual dietician for patients with cancer”) which looked at an artificial intelligence-based virtual dietitian for patients with cancer. This is based on the fact that we know nutritional status to be a key driver of patient experience and of cancer outcomes. And as the authors of the presentation noted, 80% of patients look for nutritional support, but many of them don't get it. And that's primarily a workforce issue. And I think that's an important thematic point as well, that these new technologies can help us to address some of the workforce issues we have in oncology. So this was an AI-based platform developed by experts in nutrition and cancer patients, based on peer reviewed literature, and a major effort in terms of getting all of these data up together. And they developed an artificial intelligence platform, which was predominantly text message based. And this platform was called INA. And as this is developing as a platform, there's a machine learning component to it as well. So in theory, it's going to get better and better and better over time.  And what they did in their study was they looked at little over 3,000 patients across the entire country who were suffering from various types of cancer, GU, breast, gynecological malignancy, GI and lung. And most of them had advanced-stage disease, and many of them had nutritional challenges. For example, almost 60% of them were either overweight or obese by BMI. And the patients were entered into a text exchange with the AI platform, which would give them advice on what they should eat, what they shouldn't eat. It would push various guidance and tips to them, it would develop personalized recipes for them, and it would even develop menu plans for the patients. And what's really interesting about this is that the level of engagement from the patients was very high, with almost 70% of patients actually texting questions to this platform. About 80% of the patients completed all of the surveys, and the average time that patients interacted with the platform was almost nine months, so this was remarkable levels of engagement, high levels of patient satisfaction. And although at this point, I think it's very early and somewhat subjective, there was certainly a very positive kind of vibe from patients. Nearly 50% have used the recommended recipes. More than 80% of them thought that their symptoms improved while they were using this platform. So I think as a kind of an assistant for remote management of patients, it's really remarkable. And the fact that the level of engagement was so high also means that for those patients, it's been very impactful.   The second one, this was Abstract 100 (“AI virtual patient navigation to promote re-engagement of U.S. inner city patients nonadherent with colonoscopy appointments: A quality improvement initiative”) looked again at an AI-based platform, which in this case was used in an underserved population to address healthcare disparities. This is a study from New York which was looking at colorectal cancer screening disparities amongst an underserved population, where historically they've used skilled patient navigators to address compliance with screening programs, in this case specifically for colorectal cancer. And they noticed in the background to this study that in their previous experience in 2022, almost 60% of patients either canceled or no-showed for colonoscopy appointments. And because of this and because of the high burden of patients that this group has, they decided to take an AI-based virtual patient navigator called MyEleanor and introduce this into their colorectal cancer screening quality improvement.  And so they introduced this platform in April of 2023 through to the end of the year, and their plan was to target reengagements of around 2,500 patients who had been non adherent with colonoscopy appointments in a previous year. And so the platform MyEleanor would call the patients to discuss rescheduling, it would assess their barriers to uptake, it would offer live transfer to somebody to schedule for them, and then it would go on closer to the point of the colonoscopy to call the patients and give them advice about their prep. And it was very nuanced. The platform would speak in both English and Spanish versions. It could detect nuances in the patient's voice, which might then trigger it to refer the patient to a live agent rather than the AI platform. So, very sophisticated technology. And what was most interesting about this, I think, was that over the eight months of the study, around 60% of patients actually engaged with this platform, with almost 60% of that group, or 33% overall, accepting a live transfer and then going on to scheduling, so that the completion rate for the no show patients went from 10% prior to the introduction of this platform to 19% after it was introduced. So [this is] another example, I think, of something which addresses a workforce problem and also addresses a major disparity within cancer care at the moment by harnessing these new technologies. And I think, again, a great interaction of very, very high-level science with things that make a real difference to our patients.  So, Dr. DeMichele, those are a couple of examples, I think, of early data which really are beginning to show us the potential and signal the impact that artificial intelligence is going to have for our patients in oncology. I wonder, do you have any thoughts right now of where you see the biggest impact of artificial intelligence; let's say not in 20 years from now, but maybe in the next year or two?  Dr. Angela DeMichele: Well, I think that those were two excellent examples. A really important feature of AI is really easing the workload on physicians. And what I hope will happen is that we'll be able to use AI in the very near future as a partner to really offload some of the quite time-consuming tasks, like charting, documentation, that really take us away from face-to-face interaction with patients. I think this has been a very difficult period where we move to electronic medical records, which are great for many reasons, but have really added to the burden to physicians in all of the extra documentation. So that's one way, I think, that we will hope to really be able to harness this. I think the other thing these abstracts indicate is that patients are very willing to interact with these AI chatbots in a way that I think, as you pointed out, the engagement was so high. I think that's because they trust us to make sure that what we're doing is still going to be overseen by physicians, that the information is going to get to us, and that they're going to be guided. And so I think that in areas where we can do outreach to patients, reminders, this is already happening with mammograms and other sorts of screening, where it's automated to make sure you're giving reminders to patients about things that they need to do for some of their basic health maintenance. But here, really providing important information – counseling that can be done by one of these chatbots in a way that is compassionate, informative and does not feel robotic to patients.   And then I was really impressed with, in the abstract on the screening colonoscopy, the ability of the AI instrument to really hear nuances in the patient's responses that could direct them directly to a care provider, to a clinician, if they thought that there might be some problem the patient was experiencing. So again, this could be something that could be useful in triaging phone calls that are coming in from patients or our portals that just feel like they are full of messages, no matter how hard you try to clear them all out, to get to them all. Could we begin to use AI to triage some of the more mundane questions that don't require a clinician to answer so that we can really focus on the things that are important, the things that are life threatening or severe, and make sure that we're getting to patients sooner? So there's just a few ways I really hope it'll help us. Dr. John Sweetenham: Yeah, absolutely. I think we're just scratching the surface. And interestingly enough, in my newsfeed this morning through email, I have an email that reads, “Should AI pick immunotherapy combinations?” So we'll see where that goes, and maybe one day it will. Who knows? Dr. Angela DeMichele There was a great study presented at ASCO about that very thing, and I think that is still early, but I could envision a situation where I could ask an AI instrument to tell me all of the data around something that I want to know about for a patient that could deliver all of the data to me in real time in the clinic to be able to help me make decisions, help me quote data to patients. I think in that way it could be very, very helpful. But it'll still need the physicians to be putting the data into context and thinking about how to apply it to the individual person. Dr. John Sweetenham: Absolutely, yes. And so just to round off, the final abstract that caught my eye, which I think kind of expands on a theme that we saw at an ASCO meeting two or three years ago around the impact of [oncology] care at home, and this was Abstract 1503 (“Acute care and overall survival results of a randomized trial of a virtual health intervention during routine cancer treatment”). So, a virtual platform but not AI in this case. And this was a study that looked at the use of an Integrative Medicine at Home virtual mind-body fitness program. And this was a platform that was used to look at hospital admission and acute care of patients who used it, and also looked at survival, interestingly enough. So what was done in this study was a small, randomized study which looked at the use of virtual live mind, body and fitness classes, and compared this in a randomized fashion to what they called enhanced usual care, which essentially consisted of giving the patients, making available to the patients, some pre-recorded online meditation resources that they could use. And this was applied to a number of patients with various malignancies, including melanoma, lung, gynecologic, head and neck cancers, all of whom were on systemic therapy and all of whom were reporting significant fatigue.  This was a small study; 128 patients were randomized in this study. And what was very interesting, to cut to the chase here, is that the patients who had the virtual mind-body program, compared with the control group, actually were less likely to be hospitalized, the difference there being 6.3% versus 19.1%, respectively. They spent fewer days in the hospital. And remarkably, the overall survival was 24.3 months median for patients in the usual care arm and wasn't reached in those patients who were on the virtual mind-body fitness class platform. So very preliminary data, certainly are going to need more confirmation, but another example of how it appears that many of these non-pharmacological interventions have the potential to improve meaningful endpoints, including hospital stays and, remarkably, even survival. So again, I think that that is very consistent with the theme of this year's meeting, and I found that particularly interesting, too.  I think our time is up, so I want to thank you, Dr. DeMichele, for sharing your insights with us today on the ASCO Daily News Podcast. We really appreciate it. And once again, I want to congratulate you on what was really a truly remarkable ASCO this year.  Dr. Angela DeMichele: Well, thanks so much for having me. It's been a tremendous pleasure to be with you today. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in a transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow ASCO on social media:    @ASCO on Twitter    ASCO on Facebook    ASCO on LinkedIn      Disclosures:   Dr. John Sweetenham:   Consulting or Advisory Role: EMA Wellness  Dr. Angela DeMichele: Consulting or Advisory Role (an immediate family member): Pfizer Research Funding (Inst.): Pfizer, Genentech, Novartis, Inviata/NeoGenomics  

The Marche region of Italy is a hidden gem that deserves more attention from travelers seeking authentic Italian experiences. The website Wonderful Marche is on a mission to share the beauty and charm of this unspoiled region and our chat today is all about this fabulous region. Often overlooked in favor of Italy's more famous coastlines, the Adriatic coast, home to the Marche region, offers stunning landscapes and rich cultural experiences. 
The name "Marche" is unique in that it is the only Italian region name in the plural form, reflecting its historical division into several smaller regions, known as marches.
 Join us today as we dig into the details of the Marche region and its undiscovered treasures.

Drs. Vamsi Velcheti and Nathan Pennell discuss novel approaches and key studies in lung cancer that were showcased at the 2024 ASCO Annual Meeting, including the Plenary abstracts LAURA and ADRIATIC.   TRANSCRIPT Dr. Vamsi Velcheti: Hello, I am Dr. Vamsi Velcheti, your guest host for the ASCO Daily News Podcast today. I'm a professor of medicine and director of thoracic medical oncology at the Perlmutter Cancer Center at NYU Langone Health. Today, I'm joined by Dr. Nate Pennell, the co-director of the Cleveland Clinic Lung Cancer Program and the vice chair of clinical research at the Taussig Cancer Center in Cleveland Clinic. Dr. Pennell is also the editor-in-chief of the ASCO Educational Book. Today, we will be discussing practice-changing abstracts and the exciting advances in lung cancer that were featured at the ASCO 2024 Annual Meeting. You'll find our full disclosures in the transcript of the episode. Nate, we're delighted to have you back on the podcast today. Thanks for being here. It was an exciting Annual Meeting with a lot of important updates in lung cancer. Dr. Nate Pennell: Thanks, Vamsi. I'm glad to be back. And yes, it was a huge year for lung. So I'm glad that we got a chance to discuss all of these late-breaking abstracts that we didn't get to talk about during the prelim podcast. Dr. Vamsi Velcheti: Let's dive in. Nate, it was wonderful to see all the exciting data, and one of the abstracts in the Plenary Session caught my attention, LBA3. In this study, the investigators did a comparative large-scale effectiveness trial of early palliative care delivered via telehealth versus in-person among patients with advanced non-small cell lung cancer. And the study is very promising. Could you tell us a little bit more about the study and your take-home messages? Dr. Nate Pennell: Yes, I think this was a very important study. So just to put things in perspective, it's now been more than a decade since Dr. Jennifer Temel and her group at Massachusetts General Hospital did a randomized study that showed that early interventions with palliative medicine consultation in patients with advanced non-small cell lung cancer significantly improves quality of life and in her initial study, perhaps even overall survival. And since then, there have been numerous studies that have basically reproduced this effect, showing that getting palliative medicine involved in people with advanced cancer, multiple different cancer types, really, has benefits.  The difficulty in applying this has been that palliative care-trained specialists are few and far between, and many people simply don't have easy access to palliative medicine-trained physicians and providers. So with that in mind, Dr. Temel and her group designed a randomized study called the REACH PC trial, where 1,250 patients were randomized with advanced non-small cell lung cancer to either in-person palliative medicine visits which is sort of the standard, or one in-person assessment followed by monthly telemedicine video visits with palliative medicine. Primary endpoint was essentially to show that it was equivalent in terms of quality of life and patient satisfaction. And what was exciting about this was that it absolutely was. I mean, pretty much across the board in all the metrics that were measured, the quality-of-life, the patient satisfaction, the anxiety and depression scores, all were equivalent between doing telemedicine visits and in-person visits. And this hopefully will now extend the ability to get this kind of benefit to a much larger group of people who don't have to geographically be located near a palliative medicine program. Dr. Vamsi Velcheti: Yeah, I think it's a great abstract, Nate and I actually was very impressed by the ASCO committee for selecting this for the Plenary. We typically don't see supportive care studies highlighted in such a way at ASCO. This really highlights the need for true interdisciplinary care for our patients. And as you said, this study will clearly address that unmet need in terms of providing access to palliative care for a lot of patients who otherwise wouldn't have access. I'm really glad to see those results. Dr. Nate Pennell: It was. And that really went along with Dr. Schuchter's theme this year of bringing care to patients incorporating supportive care. So I agree with you.  Now, moving to some of the other exciting abstracts in the Plenary Session. So we were talking about how this was a big year for lung cancer. There were actually 3 lung cancer studies in the Plenary Session at the Annual Meeting. And let's move on to the second one, LBA4, the LAURA study. This was the first phase 3 study to assess osimertinib, an EGFR tyrosine kinase inhibitor, in patients with EGFR mutant, unresectable stage III non-small cell lung cancer. What are your takeaways from this study?  Dr. Vamsi Velcheti: This is certainly an exciting study, and all of us in the lung community have been kind of eagerly awaiting the results of the study. As you know, for stage III non-small cell lung cancer patients who are unresectable, the standard of care has been really established by the PACIFIC study with the consolidation durvalumab after definitive concurrent chemoradiation. The problem with that study is it doesn't really answer the question of the role of immunotherapy in patients who are never-smokers, and especially in patients who are EGFR positive tumors, where the role of immunotherapy in a metastatic setting has always been questioned. And in fact, there have been several studies as you know, in patients with EGFR mutation positive metastatic lung cancer where immunotherapy has not been that effective. In fact, in the subgroup analysis in the PACIFIC study, patients with EGFR mutation did not really benefit from adding immunotherapy.  So this is an interesting study where they looked at patients with locally advanced, unresectable stage III patients and they randomized the patients 2:1 to osimertinib versus placebo following concurrent or sequential tumor radiation. The primary endpoint for the study was progression free survival, and a total of 216 patients were enrolled and 143 patients received a study treatment, which is osimertinib, and 73 received placebo. And 80% of the patients on the placebo arm crossed over to getting treatment at the time of progression.  So most of us in the lung cancer community were kind of suspecting this would be a positive trial for PFS. But however, I think the magnitude of the difference was truly remarkable. The median PFS in the osimertinib arm was 39.1 months and placebo was 5.6 months and the hazard ratio of 0.16. So it was a pretty striking difference in terms of DFS benefit with the osimertinib consolidation following chemoradiation. So it was truly a positive study for the primary endpoint and the benefit was seen across all the subgroups and the safety was no unexpected safety signals other than a slight increase in the radiation pneumonitis rates in patients receiving osimertinib and other GI and skin tox were kind of as expected. In my opinion, it's truly practice changing and I think patients with EGFR mutation should not be getting immunotherapy consolidation post chemoradiation. Dr. Nate Pennell: I completely agree with you. I think that this really just continues the understanding of the use of osimertinib in EGFR-mutant lung cancer in earlier stages of disease. We know from the ADAURA trial, presented twice in the Plenary at the ASCO Annual Meeting, that for IB, stage II and resectable IIIA, that you prolong progression free or disease free survival. So this is a very similar, comparable situation, but at an even higher risk population or the unresectable stage III patients. I think that the most discussion about this was the fact that the osimertinib is indefinite and that it is distinct from the adjuvant setting where it's being given for three years and then stopped. But I think all of us had some pause when we saw that after three years, especially in the stage III patients from ADAURA, that there were clearly an increase in recurrences after stopping the drug, suggesting that there are patients who are not cured with a time limited treatment, or at least with 3 years of treatment.  The other thing that is sobering from the study, and was pointed out by the discussant, Dr. Lecia Sequist, is if you look at the two-year disease-free survival in the placebo arm, it was only 13%, meaning almost no one was really cured with chemo radiation alone. And that really suggests that this is not that different from a very early stage IV population where indefinite treatment really is the standard of care. I wonder whether you think that's a reasonable approach. Dr. Vamsi Velcheti: I completely agree with you, Nate, and I don't think we cure a majority of our patients with stage III, and less so in patients who have EGFR-mutant, stage III locally advanced. As you just pointed out, I think very few patients actually make it that far along. And I think there's a very high rate of CNS micrometastatic disease or just systemic micrometastatic disease in this population that an effective systemic therapy of osimertinib can potentially have long term outcomes. But again, we perhaps don't cure a vast majority of them. I think that the next wave of studies should incorporate ctDNA and MRD-based assays to potentially identify those patients who could potentially go off osimertinib at some point. But, again, outside of a trial, I would not be doing that. But I think it's definitely an important question to ask to identify de-escalation strategies with osimertinib. And even immunotherapy for that matter, I think we all know that not all patients really require years and years of immunotherapy. They're still trying to figure out how to use immunotherapy in these post-surgical settings, using the MRD to de-escalate adjuvant therapies. So I think we have to have some sort of strategy here. But outside of a clinical trial, I will not be using those assays here to cite treatments, but certainly an important question to ask.  Moving on to the other exciting late-breaking abstracts, LBA5, the ADRIATIC study. This is another study which was also in the plenary session. This study was designed to address this question of consolidation immunotherapy, post chemo radiation for limited-stage small cell cancer, the treatment arms being durvalumab tremelimumab, and durvalumab observation. So what do you think about the study? This study also received a lot of applause and a lot of attention at the ASCO meeting. Dr. Nate Pennell: It was. It was remarkable to be there and actually watch this study as well as the LAURA study live, because when the disease free survival curves and in the ADRIATIC study, the overall survival curves were shown, the speakers were both interrupted by standing ovation of applause just because there was a recognition that the treatment was changing kind of before our eyes. I thought that was really neat. So in this case, I think this is truly a historic study, not necessarily because it's going to necessarily be an earth shakingly positive study. I mean, it was clearly a positive study, but more simply because of the disease in which it was done, and that is limited-stage small cell lung cancer. We really have not had a change in the way we've treated limited-stage small cell lung cancer, probably 25 years. Maybe the last significant advances in that were the advent of concurrent chemotherapy and radiation and then the use of PCI with a very modest improvement in survival. Both of those, I would say, are still relatively modest advances.  In this case, the addition of immunotherapy, which we know helps patients with small cell lung cancer - it's of course the standard of care in combination chemotherapy for extensive stage small cell lung cancer - in this case, patients who completed concurrent chemo radiation were then randomized to either placebo or durvalumab, as well as the third arm of durvalumab tremelimumab, which is not yet been recorded, and co primary endpoints were overall survival and progression free survival. And extraordinarily, there was an improvement in overall survival seen at the first analysis, with a median overall survival of 55.9 months compared to 33.4 months, hazard ratio of 0.73. So highly clinically and statistically significant, that translates at three years to a difference in overall survival of 56.5%, compared to 47.6%, or almost 10% improvement in survival at three years.  There was also a nearly identical improvement in progression-free survival, also with a hazard ratio of 0.76, suggesting that there's a modest number of patients who benefit. But it seems to be a clear improvement with the curves plateauing out. In my opinion, this is very comparable to what we saw with the PACIFIC study in stage III, unresectable non-small cell lung cancer, which immediately changed practice back when that first was reported. And I expect that this will change practice pretty much immediately for small cell as well. Dr. Vamsi Velcheti: Yeah, I completely agree, Nate. I think it's an exciting advance in patients with limited-stage small cell lung cancer. For sure, it's practice-changing, and I think the results were exciting.  So one thing that really intrigued me was in the extensive-stage setting, the benefit was very mediocre with one-to-two month overall survival benefit in both the PACIFIC and in IMpower trial. Here we are seeing almost two-year of median OS benefit. I was kind of puzzled by that, and I thought it may have to do with patients receiving radiation. And we've seen that with the PACIFIC, and makes you wonder if both the CASPIAN and the IMpower studies actually did not allow consolidation thoracic radiation. Hypothetically, if they had allowed consolidation thoracic radiation, perhaps we would have seen better outcomes. Any thoughts on that? Dr. Nate Pennell: We've been trying to prove that radiation and immunotherapy somehow go together better for a long time. Going back to the first description of the abscopal effect, and I'm not sure if I necessarily believe that to be the case, but in this setting where we truly are trying to cure people rather than merely prolong their survival, maybe this is the situation where it truly is more beneficial. I think what we're seeing is something very similar to what we're seen in PACIFIC, where in the stage IV setting, some people have long term survival with immunotherapy, but it's relatively modest. But perhaps in the curative setting, you're seeing more of an impact. Certainly, looking at these curves, we'll have to see with another couple of years to follow up. But a three-year survival of 56% is pretty extraordinary, and I look forward to seeing if this really maintains over the next couple of years follow up.  Moving beyond the Plenary, there were actually lots of really exciting presentations, even outside the Plenary section. One that I think probably got at least as much attention as the ones that we've already discussed today was actually an update of an old trial that's been presented for several prior years. And I'm curious to get your take on why you thought this was such a remarkable study. And we're talking about the LBA8503, which was the 5-year update from the CROWN study, which looked at previously untreated ALK-positive advanced non-small cell in cancer patients randomly assigned to lorlatinib, the third generation ALK inhibitor, versus crizotinib, the first generation ALK inhibitor. What was so exciting about this study, and why were people talking about it?  Dr. Vamsi Velcheti: Yeah, I agree, Nate. We've seen the data in the past, right? Like on the CROWN data, just first like a quick recap. This is the CROWN study, like the phase 3 study of third generation ALK inhibitor lorlatinib. So global randomized phase 3 study in patients with metastatic disease randomized to lorlatinib versus crizotinib, which is a controller. So the primary endpoint was PFS, and we've seen the results in the past of the CROWN readout quoted, with a positive study and the lorlatinib received FDA approval in the frontline setting. But the current study that was presented at the ASCO annual meeting is a kind of a postdoc analysis of five years. The endpoint for the study with central review stopped at three years, and this is actually a follow up beyond that last readout. Interestingly, in this study, when they looked at the median PFS at five years, the lorlatinib arm did not reach a median PFS even at five years and the hazard ratio is 0.19, which is kind of phenomenal in some ways. At 5 years, the majority of the patients were still on the drug. So that's quite incredible. And the benefit was more profound in patients with brain mets with a hazard ratio of 0.08. And again, speaking to the importance of brain penetrant, small molecule inhibitors, and target therapy, the safety profile, there were no additional safety signals noted in the study. We kind of know about the side effects of lorlatinib already from previous studies readouts. No unusual long-term toxicities.  I should note though, about 40% of patients did have CNS, AEs grade 1, 2 CNS toxicities on the  lorlatinib arm. And the other interesting thing that was also reported in the trial was dose reduction of lorlatinib did not have an impact on the PFS, which is interesting in my opinion. They also did some subgroup analysis, biomarker testing, biomarker populations. Patients who had P53 cooperation did much better with lorlatinib versus crizotinib. So overall, the other thing that they also had shown on the trial was the resistance mechanisms that were seen with lorlatinib were very different than what we are used to seeing with the earlier generation ALK inhibitors. The majority of the patients who develop resistance have bypass mechanisms and alterations in MAP kinase pathway PI3K/MTOR/PTEN pathway, suggesting that lorlatinib is a very potent ALK inhibitor and on target ALK mutations don't happen as frequently as we see with the earlier generation ALK inhibitors.  So I think this really begs the question, should we offer lorlatinib to all our patients with metastatic ALK-positive tumors? I think looking at the long-term data, it's quite tempting to say ‘yes', but I think at the same time we have to take into consideration patient safety tolerability. And again, the competitor arm here is crizotinib. So lorlatinib suddenly seems to be, again, cross trial comparisons, but I think the long-term outcomes here are really phenomenal. But at the same time, I think we've got to kind of think about patient because these patients are on these drugs for years, they have to live with all the toxicities. And I think the patient preferences and safety profile matters in terms of what drug we recommend to patients. Dr. Nate Pennell: I completely agree with you. I think the right answer, is that this has to be an individual discussion with patients. The results are incredibly exciting. I mean, the two-year progression free survival was 70%, and the five-year, three years later is still 60%. Only 10% of people are failing over the subsequent three years. And the line is pretty flat. And as you said, even with brain metastases, the median survival is in reach. It's really extraordinary. Moreover, while we do talk about the significant toxicities of lorlatinib, I thought it was really interesting that only 5% of people were supposedly discontinued the drug because of treatment related AEs, which meant that with dose reduction and management, it seems as though most patients were able to continue on the drug, even though they, as you mentioned, were taking it for several years.  That being said, all of us who've had experience with the second-generation drugs like alectinib and brigatinib, compared to the third-generation drug lorlatinib, can speak to the challenges of some of the unique toxicities that go along with it. I don't think this is going to be a drug for everyone, but I do think it is now worth bringing it up and discussing it with the patients most of the time now. And I do think that there will be many people for whom this is going to be a good choice, which is exciting. Dr. Vamsi Velcheti: Absolutely, completely agree. And I think there are newer ALK inhibitors in clinical development which have cleaner and better safety profiles. So we'll have to kind of wait and see how those pan out.  Moving on to the other exciting abstract, LBA8509, the KRYSTAL-12 study. LBA8509 is a phase 3 study looking at adagrasib versus docetaxel in patients with previously treated advanced metastatic non-small cell cancer with KRASG12C mutation. Nate, there's been a lot of hype around this trial. You've seen the data. Do you think it's practice-changing? How does it differentiate with the other drug that's already FDA approved, sotorasib?  Dr. Nate Pennell: Yeah, this is an interesting one. I think we've all been very excited in recent years about the identification of KRASG12C mutations as targetable mutations. We know that this represents about half of KRAS mutations in patients with non-small cell lung cancer, adenocarcinoma, and there are two FDA-approved drugs. Sotorasib was the first and adagrasib shortly thereafter. We already had seen the CodeBreaK 200 study, which was a phase 3 study of sotorasib versus docetaxel that did modestly prolong progression free survival compared to docetaxel, although did not seem to necessarily translate to an improvement in overall survival. And so now, coming on the heels of that study, the KRYSTAL-12 study compared adagrasib, also the KRASG12C  inhibitor versus docetaxel and those with previously treated non-small cell with KRASG12C. And it did significantly improve progression free survival with a hazard ratio of 0.58. Although when you look at the median numbers, the median PFS was only 5.5 months with the adagrasib arm compared to 3.8 months with docetaxel. So while it is a significant and potentially clinically significant difference, it is still, I would say a modest improvement.   And there were some pretty broad improvements across all the different subgroups, including those with brain metastases. It did improve response rate significantly. So 32% response rate without adagrasib, compared to only 9% with docetaxel. It's about what you would expect with chemotherapy. And very importantly, in this patient population, there was activity in the brain with an intracranial overall response rate among those who had measurable brain metastases of 40%. So certainly important and probably that would distinguish it from drugs like docetaxel, which we don't expect to have a lot of intracranial toxicity. There is certainly a pattern of side effects that go along with that adagrasib, so it does cause especially GI toxicity, like diarrhea, nausea, vomiting, transaminitis. All of these were actually, at least numerically, somewhat higher in the adagrasib arm than in docetaxel, a lot more hematologic toxicity with the docetaxel. But overall, the number of serious adverse events were actually pretty well matched between the two groups. So it wasn't really a home run in terms of favorable toxicity with that adagrasib.  So the question is: “In the absence of any data yet on overall survival, should this change practice?” And I'm not sure it's going to change practice, because I do think that based on the accelerated approval, most physicians are already offering the G12C inhibitors like sotorasib and adagrasib, probably more often than chemotherapy, I think based on perceived improvement in side effects and higher response rates, modestly longer progression-free survival, so I think most people think that represents a modest improvement over chemotherapy. And so I think that will continue. It will be very interesting, however, when the overall survival report is out, if it is not significantly better, what the FDA is going to do when they look at these drugs.  Dr. Vamsi Velcheti: Thanks so much. Very well summarized. And I do agree they look more similar than dissimilar. I think CodeBreaK-200 and the KRYSTAL-12, they kind of are very identical. I should say, though I was a little surprised with the toxicity profile of adagrasib. It seemed, I mean, not significantly, but definitely seemed worse than the earlier readouts that we've seen. The GI tox especially seems much worse on this trial. I'm kind of curious why, but if I recall correctly, I think 5% of the patients had grade 3 diarrhea. A significant proportion of patients had grade 3 nausea and vomiting. And the other complicating thing here is you can't use a lot of the antiemetics because of the QT issues. So that's another problem. But I think it's more comparable to sotorasib, in my opinion.  Dr. Nate Pennell: While this is exciting, I like to think of this as the early days of EGFR, when we were using gefitinib and erlotinib. They were certainly advances, but we now have drugs that are much more effective and long lasting in these patients. And I think that the first-generation inhibitors like sotorasib and adagrasib, while they certainly benefit patients, now is just the beginning. There's a lot of research going on, and we're not going to talk about some of the other abstracts presented, but some of the next generation G12C inhibitors, for example, olomorasib, which did have also in the same session, a presentation in combination with pembrolizumab that had a very impressive response rate with potentially fewer side effects, may end up replacing the first generation drugs when they get a little bit farther along. And then moving on to another one, which I think potentially could change practice. I am curious to hear your take on it, was the LBA8505, which was the PALOMA-3 study. This was interesting in that it compared two different versions of the same drug. So amivantamab, the bispecific, EGFR and MET, which is already approved for EGFR exon 20 non-small cell lung cancer, in this case, in more typical EGFR-mutated non-small cell lung cancer in combination with osimertinib with the intravenous amivantamab, compared to the subcutaneous formulation of amivantamab. Why would this be an important study? Dr. Vamsi Velcheti: I found this study really interesting as well, Nate. And as you know, amivantamab has been FDA approved for patients with exon 20 mutation. And also, we've had, like two positive readouts in patients with classical EGFR mutations. One, the MARIPOSA study in the frontline setting and the MARIPOSA-2, in the second-line post osimertinib setting. For those studies, the intravenous amivantamab was used as a treatment arm, and the intravenous amivantamab had a lot of baggage to go along with it, like the infusion reactions and VTEs and other classic EGFR related toxicity, skin toxicities. So the idea behind developing the subcutaneous formulation of amivantamab was mainly to reduce the burden of infusion, infusion time and most importantly, the infusion related reactions associated with IV formulation.  In a smaller phase 2 study, the PALOMA study, they had looked at various dosing schemas like, subcutaneous formulation, and they found that the infusion related reactions were very, very low with the subcutaneous formulation. So that led to the design of this current study that was presented, the PALOMA-3 study. This was for patients who had classical EGFR mutations like exon 19, L858R. The patients were randomized 1:1 to subcutaneous amivantamab with lazertinib versus IV amivantamab plus lazertinib. The endpoints for the study, it's a non-inferiority study with co primary endpoints of C trough and C2 AUC, Cycle 2 AUC. They were looking at those pharmacological endpoints to kind of demonstrate comparability to the IV formulation. So in this study, they looked at these pharmacokinetic endpoints and they were essentially identical. Both subcutaneous and IV formulations were compatible. And in terms of clinical efficacy as well, the response rate was identical, no significant differences. Duration of response was also identical. The PFS also was comparable to the IV formulation. In fact, numerically, the subcutaneous arm was a little better, though not significant. But it appears like, you know, the overall clinical and pharmacological profile of the subcutaneous amivantamab was comparable. And most interestingly, the AE profile, the skin toxicity was not much different. However, the infusion reactions were substantially lower, 13% with the subcutaneous amivantamab and 66% with IV amivantamab. And also, interestingly, the VTE rates were lower with the subcutaneous version of amivantamab. There was still a substantial proportion of patients, especially those who didn't have prophylactic anticoagulation. 17% of the patients with the subcutaneous amivantamab had VTE versus 26% with IV amivantamab. With prophylaxis, which is lower in both IV and subcutaneous, but still subcutaneous formulation at a lower 7% versus 12% with the IV amivantamab.  So overall, I think this is an interesting study, and also the authors had actually presented some interesting data on administration time. I've never seen this before. Patients reported convenience using a modified score of patient convenience, essentially like patients having to spend a lot of time in the infusion site and convenience of the patient getting the treatment. And it turns out, and no surprise, that subcutaneous amivantamab was found to be more convenient for patients.  So, Nate, I want to ask you your take on this. In a lot of our busy infusion centers, the time it takes for those patients to get the infusion does matter, right? And I think in our clinic where we are kind of fully booked for the infusion, I think having the patients come in and leave in 15, 20 minutes, I think it adds a lot of value to the cancer center operation.  Dr. Nate Pennell: Oh, I completely agree. I think the efficacy results were reassuring. I think the infusion related reaction difference, I think is a huge difference. I mean, I have given a fair amount of amivantamab, and I would say the published IRR rate of 66%, 67% I would say, is maybe even underestimates how many patients get some kind of reaction from that, although it really is a first dose phenomenon. And I think that taking that down to 13% is a tremendous advance. I think fusion share time is not trivial as we get busier and busier. I know our cancer center is also very full and it becomes challenging to schedule people, and being able to do a five-minute treatment versus a five-hour treatment makes a big difference for patients.  It's interesting, there was one slide that was presented from an efficacy standpoint. I'm curious about your take on this. They showed that the overall survival was actually better in the subcu amivantamab arm, hazard ratio of 0.62. Now, this was only an exploratory endpoint. They sort of talk about perhaps some rationale for why this might be the case. But at the very least, I think we can be reassured that it's not less effective to give it and does seem to be more tolerable and so I would expect that this hopefully will be fairly widely adopted. Dr. Vamsi Velcheti: Yeah, I agree. I think this is a welcome change. Like, I think the infusion reactions and the resources it takes to get patients through treatments. I think it's definitely a win-win for patients and also the providers.  And with that, we come to the conclusion of the podcast. Nate, thank you so much for the fantastic insights today. Our listeners will find all the abstracts discussed today in the transcripts of the episode. Thank you so much for joining us today, Dr. Pennell.  Dr. Nate Pennell: Oh, thanks for inviting me. It's always fun to talk about all these exciting advances for our patients. Dr. Vamsi Velcheti: Thanks to our listeners for your time today. You will find links to all the abstracts discussed today in the transcript of the episode. Finally, if you value the insights that you hear from ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcast.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:    Dr. Vamsi Velcheti  @VamsiVelcheti    Dr. Nathan Pennell  @n8pennell    Follow ASCO on social media:      @ASCO on Twitter    ASCO on Facebook    ASCO on LinkedIn      Disclosures:  Dr. Vamsi Velcheti:  Honoraria: ITeos Therapeutics  Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus  Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline  Dr. Nathan Pennell:    Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron   Research Funding (Inst): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi

Lots and lots of updates from the past weekend's ASCO annual meeting. 1. ADRIATIC (consolidation durvalumab in limited stage SCLC) 2. NADINA (neoadjuvant Nivo/Ipi in stage III melanoma) 3. *NICHE-2 (neoadjuvant Nivo/Ipi in dMMR colon cancer) 4. CheckMate 8HW (Nivo/Ipi in dMMR metastatic colon cancer) 5. TRANSMET (liver transplantation in colon cancer with liver mets) 6. Eposec (FLOT > CROSS in adenocarcinoma of the esophagus) 7. LAURA (forever osimertinib in stage III EGFR-mutated NSCLC post-chemoRT) 8. CROWN (5 year update of lorlatinib in ALK+ NSCLC) 9. Destiny Breast-06 (T-DXd vs. chemo in HER-2 low and "ultra" low MBC who haven't received chemo in metastatic setting) 10. ASC4FIRST (Asciminib first line in CML. Funny title, amirite?)

Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Alyssa: Hi Dr. Cabral, Have you hear of the supplement Perfect Amino by Body Health and if so what is your opinion? They claim it has all of the essential amino acids and is a 90% absorption rate within 30 mins of taking them, unlike other protein powders that are mostly converted to sugar. Also says it won't break a fast as it is only 2 calories. Thanks   Seth: Hey Doc, I was just listening to the podcast that you asked for help to make it easier for people to find the info they're looking for. Manychat and other chat bots might be a great start. Or create a section in your app that does this? Anyway my question for you is: I've done the cbo 2 times in a row because I tested high in yeast and bacteria. The peculiar thing is that both times I did the cbo, week 4 of the 2nd month was when i had the most relief. Then I gradually get worse and back to where I started. I'm 98% dairy and gluten free, I eat low inflammatory 90%. Don't drink alcohol, rarely do sweets. Lift heavy weights, sleep at leat 7.5 hrs. Maybe it's a parasite(s)? Either way I believe something in the supplements for month 2 helped more than others...thanks broski   Stacy: Hi Dr. Cabral. I really enjoy listening to your podcasts! My question is, can an infrared sauna blanket cause issues in people who are sensitive to heat? I don't really know if I'm sensitive to heat, but I do have thyroid disease. I started using my infrared, sauna blanket, eight months ago and within a few weeks my left shoulder started hurting really bad and my left hand went numb, this happened until I stopped using my sauna. I gave it a couple month break and then I started it back up at lowest temp for only 15 min each time. Within 2 weeks it started happening again. Any ideas why?   Dionna: Hi, Dr. Cabral. I am about to go into month 3 of the CBO Protocol next week. I still have some bloating with my smoothie, lunch and dinner. I'm not eating anything that was on my food sensitivity list, but I have noticed that ginger is in some of the Equilife supplements I'm taking, and ginger was a food sensitivity. Is some amount of bloating after meals normal, or could the ginger be an issue? I'm so worried about going through all of this and my gut not being fully healed when done. My gut was in pretty bad shape for years with what I now know was yeast and bacteria overgrowth. Does the CBO protocol ever NOT heal the gut when done correctly? Do some people have to do it twice? Thank you for helping the world to be a better place! Dionna   Lara: Hi, dr. C :) I'm wondering about sriracha.. is it healthy, do you use it? How about salt.. iodized is considered unhealthy, why? Which is best? We live at the top of the Adriatic sea which basically means it's a huge bay between Slovenia & Italy so I don't think the sea here is super clean, but everyone swears our sea salt is the best.. and that Himalayan salt is coloured, how can we know which one is best? ..and how about black salt? Vegans use it to make chickpea omelettes taste more like eggs but is that a healthy salt? WebMD says it has antioxidants & lots of minerals, but we trust you the most.. Thank you for clearing all of that up for us.. you're absolutely amazing, I listen to you every day!   Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes and Resources: StephenCabral.com/3019 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!